Fibroblast growth factor signaling in ovarian cancer by Brantner, Manuel
1 
 
 
 
 
DIPLOMARBEIT 
 
Titel der Diplomarbeit  
„Fibroblast growth factor signaling in 
ovarian cancer“ 
 
Verfasser 
Manuel Brantner 
 
angestrebter akademischer Grad 
Magister der Naturwissenschaften (Mag. rer. nat.) 
 
Wien, 2012 
 
Studienkennzahl laut Studienblatt: A 490 
Studienrichtung laut Studienblatt:  Diplomstudium Molekulare Biologie 
Betreuer:    Ass-Prof. Dr. Joachim Seipelt  
2 
 
  
3 
 
 
 
This diploma thesis was performed at the 
 
Medical University of Vienna 
Department of Internal Medicine I 
Division of Clinical Oncology 
 
 
and supervised by 
 
Univ. Prof. Mag. Dr. Thomas Grunt 
  
4 
 
  
5 
 
Danksagung 
Ich möchte mich herzlich bei all jenen Personen bedanken, die mich auf 
vielfält ige Weise unterstützt und zu dieser Diplomarbeit  beigetragen 
haben. 
An erster Stelle richtet sich mein Dank an Herrn Univ. Prof. Mag. Dr. Thomas 
Grunt für die Themenstellung, Finanzierung und Betreuung sowie die 
Korrektur meiner Diplomarbeit . Auch möchte ich Frau Renate Wagner für 
die Einschulung und die technische Unterstützung im Labor danken. 
Ein großer Dank gilt  Ao. Univ. Prof. Dr. Walter Berger, Priv. Doz. Dr. Michael 
Grusch, Ao. Univ. Prof. Dr. Brigitte Marian, Ao. Univ. Prof. Klaus Holzmann 
und Ao. Univ. Prof. Bett ina Grasl-Kraupp vom Inst itut für Krebsforschung für 
die herzliche Aufnahme in das wöchentliche „FGF-meeting“, ihre Expert ise 
und die unzähligen guten Ratschläge. Herrn Priv. Doz. Michael Grusch und 
Ao. Univ. Prof. Walter Berger möchte ich außerdem für die Bereitstellung 
der FGF- und FGFR-Primer danken. 
Herrn Ass-Prof. Dr. Joachim Seipelt  danke ich für die offizielle Betreuung 
meiner Diplomarbeit  und ganz besonders für die Beratung bezüglich 
meiner beruflichen Zukunft. 
Frau Dr. Nelly Auersperg danke ich für die Bereitstellung der Zelllinien 
IOSE-80, IOSE-364 und IOSE-386. 
Mein besonderer Dank gilt  meinen Eltern Edith und Ludwig und meiner 
Schwester Katharina, die immer an mich geglaubt haben und ohne deren 
Unterstützung ich nicht in der Lage gewesen wäre, mein Studium 
erfolgreich abzuschließen. Großer Dank gebührt auch Viktoria Smolle für 
ihre liebevolle Unterstützung und Geduld. 
 
Herzlichen Dank! 
6 
 
  
7 
 
Table of content 
 
1 Abstract.......................................................................................... 11 
2 Zusammenfassung ....................................................................... 13 
3 Introduction ................................................................................... 15 
3.1 Ovarian cancer ..............................................................................................15 
3.2 Fibroblast growth factor signaling.............................................................21 
3.2.1 Fibroblast growth factor receptors ....................................................21 
3.2.2 Structure of fibroblast growth factor receptors .............................24 
3.2.3 Fibroblast growth factors ......................................................................27 
3.2.4 FGF-FGFR signaling system ...................................................................28 
3.2.5 FGF receptor downstream signaling.................................................30 
3.2.6 Aberrant FGF signaling and cancer..................................................31 
3.2.7 Carcinogenic mechanisms of aberrant FGF signaling ................33 
3.2.8 Inhibit ion of FGF signaling .....................................................................34 
4 Materials and Methods ............................................................... 36 
5 Results............................................................................................. 53 
5.1 Analysis of fibroblast growth factor receptor splice variants ............53 
5.1.1 Fibroblast growth factor receptor 1 ..................................................53 
5.1.2 Fibroblast growth factor receptor 2 ..................................................54 
5.1.3 Fibroblast growth factor receptor 3 ..................................................55 
5.1.4 Fibroblast growth factor receptor 4 ..................................................56 
5.2 Expression profile of FGFR isoforms in ovarian cancer cell lines  .......57 
5.3 Expression profile of FGFs in ovarian cancer cell lines ........................59 
5.4 Potential autocrine signaling loops in ovarian cancer cells  .............60 
8 
 
5.5 Modulat ion of Ras/MAPK and PI3K downstream effectors by FGF-1, 
FGF-2 and condit ioned growth medium in ovarian cancer cells  ............. 63 
5.5.1 FGF-1 and FGF-2 trigger activation of the Ras/MAPK pathway, 
but not of the PI3K-pathway in A-2780, OVCAR-3 and SKOV-3 ovarian 
cancer cells ............................................................................................................ 63 
5.5.2 FGF-1 and FGF-2 are not capable of activating Ras/MAPK in 
HEY ovarian cancer cells .................................................................................... 65 
5.6 Influence of FGF-1 and FGF-2 on proliferat ion of ovarian cancer 
cells in vit ro ................................................................................................................. 66 
5.6.1 FGF-2 but not FGF-1 induces cell proliferat ion in A-2780 and HEY 
ovarian cancer cells ............................................................................................ 66 
5.6.2 Neither FGF-1 nor FGF-2 induce cell proliferat ion in OVCAR-3 
and SKOV-3 ovarian cancer cells .................................................................... 67 
5.7 Effects of fibroblast growth factors on migrat ion of A-2780, HEY and 
SKOV-3 ovarian cancer cells ................................................................................ 68 
5.8 Impact of FGFR inhibit ion on survival and proliferat ion of ovarian 
cancer cells in vit ro .................................................................................................. 70 
5.8.1 Fibroblast growth factor receptor signaling is crucial for 
proliferat ion of A-2780 ovarian cancer cells................................................. 70 
5.8.2 PD173074 but not Dovit inib (CHIR-258) inhibits HEY ovarian 
cancer cell proliferat ion ..................................................................................... 71 
5.8.3 Neither PD173074 nor Dovit inib (CHIR-258) inhibits OVCAR-3 
ovarian cancer cell proliferat ion at clinical relevant concentrat ions .. 72 
5.8.4 PD173074 and Dovit inib (CHIR-258) exhibit  similar dose response 
curves on inhibit ion of SKOV-3 ovarian cancer cell proliferat ion ........... 72 
6 Discussion ...................................................................................... 74 
7 References..................................................................................... 79 
9 
 
8 Curriculum vitae ........................................................................... 89 
 
  
10 
 
  
11 
 
1 Abstract 
 
Epithelial ovarian cancer is a rapidly progressive, highly lethal disease with 
low prevalence. It  is responsible for 20% of all cancer-related deaths in the 
United States, since few patients are diagnosed early and subsequently 
cured. Over the last decades, there has been poor therapeutic 
improvement besides cytotoxic chemotherapy and oophorectomy, but 
recent clinical t rials with inhibitors of receptor tyrosine kinases have been 
very promising. Fibroblast growth factor receptors (FGFR) are involved in 
malignant transformation, angiogenesis and chemoresistance. They have 
been identified as valuable targets for cancer therapy and inhibit ion of 
FGFR-dependent signaling was able to overcome resistance to standard 
therapies, but the underlying molecular fundamentals have not  been 
evaluated yet. The aim of this study was to characterize the FGF signaling 
system and its influence on malignancy-related cell propert ies in epithelial 
ovarian cancer cells. 
RT-PCR analysis of FGF receptors and ligands revealed, that de novo 
expression of fibroblast growth factors and their receptors leading to 
autocrine signaling loops with a strong mitogenic potential is a very 
common event in epithelial ovarian cancers (70%). As evaluated by 
immunoblott ing, the FGF signaling system in these cells is functional and 
condit ioned growth medium was able to induce phosphorylat ion of 
ERK1/2 by different degrees. Proliferat ion assays showed a significant 
increase in 50% of evaluated ovarian cancer cells when treated with 
recombinant FGF-2. FGF-1 induced migrat ion in 66% of the cells in a non-
significant manner. The dependency of ovarian cancer cells on FGF 
receptor signaling was evaluated by growth inhibit ion assays using two 
different small molecule inhibitors – PD173074, a specific inhibitor of FGF 
receptors and Dovit inib (CHIR-258), a more promiscuous inhibitor of 
receptor tyrosine kinases. A-2780 cells were found to be extremely sensit ive 
to FGF inhibit ion, while HEY and SKOV-3 cells showed moderate sensit ivity. 
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OVCAR-3 cells were figured out as resistant to inhibit ion of class I I I, IV and V 
receptor tyrosine kinases. 
Together, these data suggest that FGF receptor inhibitors have a good 
potential in t reatment of ovarian cancers alone and possibly even more in 
combination with cytotoxic agents. However, the variance in response to 
the evaluated inhibitors underlines the necessity for reliable serum markers 
for the improvement of therapeutic strategies against  epithelial ovarian 
cancer. 
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2 Zusammenfassung 
 
Das Ovarialkarzinom ist  eine sich rasch entwickelnde, tödliche, aber 
seltene Erkrankung. Trotzdem ist  sie für 20% aller mit Krebs im 
Zusammenhang stehenden Todesfälle in den Vereinigten Staaten 
verantwort lich, da die Krankheit  in den meisten Fällen spät diagnost iziert  
wird. In den letzten Jahrzehnten gab es nur wenig Verbesserung in den 
therapeutischen Strategien neben der zytotoxischen Therapie und 
Ovariektomie, aber neue Ergebnisse aus klinischen Studien mit 
niedermolekularen Inhibitoren der Familie der Rezeptortyrosinkinasen sind 
sehr vielversprechend. Die Fibroblastenwachstumsfaktoren (FGFs) und ihre 
Rezeptoren sind involviert  in maligne Transformation, Angiogenese und 
Chemoresistenz und stellen vielversprechende Zielstrukturen in der 
Krebstherapie dar, insbesondere für die Überwindung von Chemoresistenz 
gegen Zytostat ika. Die zugrunde liegenden molekularen Mechanismen 
wurden allerdings noch nicht erforscht. Das Ziel dieser Arbeit  war die 
Charakterisierung des Signalsystems der Fibroblastenwachstumsfaktoren 
und sein Einfluss auf Zelleigenschaften im Ovarialkarzinom die mit 
Malignität im Zusammenhang stehen. 
Die Analyse des FGF Rezeptors und seiner Liganden mit RT-PCR ergab, 
dass die de novo-Expression von FGFs sowie von FGF Rezeptoren im 
Ovarialkarzinom häufig zu finden ist  (70%) und zu autokrinen 
Signalschleifen mit hohem mitogenen Potential führt. Wie durch 
Immunoblott ing gezeigt wurde, ist  das Signalsystem in diesen Zellen 
funkt ionell, und kondit ioniertes Wachstumsmedium war unterschiedlich 
stark in der Lage, die Phosphorylierung von ERK1/2 zu induzieren. 
Wachstumsassays zeigten eine signifikante Steigerung der Proliferat ion bei 
der Behandlung mit FGF-2 in 50% der untersuchten Zelllinien. FGF-1 zeigte 
eine nicht-signifikante Steigerung der Motilität in 66% dieser Zellen. Die 
Abhängigkeit  von Ovarialkarzinomzellen von Signalen der FGF Rezeptoren 
wurde durch Wachstumsinhibierungsassays untersucht. Dabei wurden zwei 
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unterschiedliche, niedermolekulare Inhibitoren verwendet – PD173074, ein 
spezifischer Inhibitor der FGF Rezeptorfamilie und Dovit inib (CHIR-258), ein 
Inhibitor mit geringerer Spezifität für einzelne Rezeptoren aber mit höherer 
Bandbreite. A-2780 Zellen zeigten eine extrem hohe Sensit ivität gegen 
FGFR-Inhibierung, während HEY und SKOV-3 Zellen eine moderate 
Sensit ivität aufwiesen. OVCAR-3 Zellen zeigten eine hohe Resistenz 
gegenüber der Inhibierung von Rezeptortyrosinkinasen der Klassen I I I , IV 
und V.  
Zusammen zeigen diese Daten, dass Inhibitoren der FGF Rezeptoren ein 
gutes Potential in der Behandlung des Ovarialkarzinoms haben, 
möglicherweise aber noch mehr in Kombination mit Zytostat ika. Allerdings 
unterstreicht die starke Varianz in der Reaktion der unterschiedlichen 
Zellen auf die FGFR-Inhibierung die Notwendigkeit  zuverlässiger 
Serummarker um die therapeutischen Strategien für die Behandlung des 
Ovarialkarzinoms zu verbessern. 
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3 Introduction 
 
3.1 Ovarian cancer 
 
Ovarian cancer is a heterogeneous, rapidly progressive and highly lethal 
disease of low prevalence (Schorge et al 2010). 
Worldwide each year, 200.000 women are diagnosed with ovarian cancer 
and 125.000 die from this disease (Parkin et al 2005, Sankaranarayanan 
and Ferlay 2006). In the United States, it  is the fifth leading cause of all 
cancer-related deaths, but only the eighth leading cause of cancer in 
women (Jemal et al 2010) since few patients are diagnosed early and 
subsequently cured (Schorge et al 2010). 
The et iology of ovarian cancer is poorly understood and the exact t issue 
origin is not clear. It  has been thought that the majority of ovarian cancers 
derive from inclusion cysts from a single cell-layer of epithelium surrounding 
the ovary (Auersperg et al 2001). In fact ovarian, fallopian tube and 
primary peritoneal carcinomas have identical histological and 
morphological features and it  is believed that a high percentage of 
“ovarian cancers” actually arise in the fimbrinated end of fallopian tube or 
from components of the secondary Müllerian system with metastasis to the 
ovary (Dubeau 2008, Kindelberger et al 2007). Primary peritoneal cancers 
might also derive from these t issues (Muto et al 1995, Schorge et al 1998). 
Ovarian cancers can roughly be separated into two categories. Low-
grade tumors grow slowly, are less responsive to chemotherapy and have 
a low malignant potential. High-grade carcinomas exhibit  great genetic 
instability, are rapidly metastat ic and more chemosensit ive (Landen et al 
2008). 
Risk fact ors. Up to 10% of all ovarian cancer patients have inherited germ-
line mutations in BRCA1, BRCA2, MLH1 or MSH2 (Smith et al 2001). These 
16 
 
genes encode tumor suppressors involved in DNA strand-break repair. The 
other 90% of women exhibit  increased proliferat ion-associated DNA-
damage during their reproductive years (Purdie et al 2003, Schildkraut et 
al 1997). Women, who never gave birth, have double risk of developing 
ovarian cancer (Titus-Ernstoff et al 2001) and the probability decreases 
with each birth plateauing at about 5 delivers (Hinkula et al 2006). It  is 
generally believed that the risk increases with every menarche during a 
woman’s lifet ime and this number decreases with every pregnancy while 
breast feeding addit ionally delays resumption of menarche and therefore 
has a protective effect (Yen et al 2003). 
The opposite applies to early menarche, late menopause and nulliparity, 
which is often associated with infert ility (Tworoger et al 2007). Long-term 
use of contraceptives reduces the risk by 50% and it  is believed that 
100.000 deaths have already been prevented by those drugs  (Beral et al 
2008). White women have an elevated risk of 30-40% compared to black 
or Hispanic women for developing ovarian carcinomas. The striking 
influence of ethnic background is illustrated by European Jewish women, 
where 35-40% diagnosed with ovarian cancer possess a mutation in 
BRCA1 or BRCA2 (Smith et al 2001). Prophylactic oophorectomy can be 
considered after the age of 40 and is associated with a more than 90% 
decreased risk for the development of ovarian cancer. 
Over the last decades there was minimal progress in detecting ovarian 
cancer at a more curable early stage. The screening for serum markers, 
sonograms and pelvic examinations did not decrease mortality (Hogg and 
Friedlander 2004). CA125 tumor antigen is the most widely studied 
biomarker as it  was init ially found to be elevated in 83% of ovarian cancer 
patients (Bast et al 1983), but further studies demonstrated high false-
posit ive and false-negative rates due to several other factors modulat ing 
CA125-serum-levels (Schorge et al 2010). A large prospective study 
demonstrated that the combination of CA125 serum-levels with 
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t ransvaginal ult rasonography would lead to many unnecessary surgical 
interventions with a surgery-to-cancer-rat io of 19.5 to 1 (St irling et al 2005). 
More than 30 serum markers have been identified during the last years 
and some of them were able to provide evidence of ovarian cancer up 
to 3 years before clinical diagnosis (Anderson et al 2010) but rigorous 
validation studies are st ill pending. 
 
St aging and t reat ment  of ovarian cancer  
Stage I Growth limited to the ovaries 
  
Ia Growth limited to one ovary; no ascites present containing malignant cells. 
No tumor on external surface; capsule intact 
Ib Growth limited to both ovaries; no ascites present containing malignant 
cells. No tumor on the external surfaces; capsules intact 
Ic Tumor either stage Ia or Ib, but with tumor on surface of one or both 
ovaries, or with capsule(s) ruptured, or with ascites present containing 
malignant cells, or with positive peritoneal washings 
  
Stage II Growth involv ing one or both ovaries with pelv ic extension 
  
IIa Extension and/or metastases to the uterus and/or tubes 
IIb Extension to other pelv ic tissues 
IIc Tumor either Stage I Ia or I Ib, but with tumor on surface of one or both 
ovaries, or with capsule(s) ruptured, or with ascites present containing 
malignant cells, or with positive peritoneal washings 
  
Stage III  Tumor involv ing one or both ovaries with peritoneal implants outside 
the pelv is and/or positive regional lymph nodes. Superﬁcial liver 
metastasis equals Stage I I I . Tumor is limited to the true pelv is, but with 
malignant extension to small bowel or omentum 
  
IIIa Tumor grossly limited to the true pelv is, with negative lymph nodes, but with 
microscopic seeding of abdominal peritoneal surfaces, or extension to 
small bowel or mesentery 
IIIb Tumor of one or both ovaries with implants, peritoneal metastasis of 
abdominal peritoneal surfaces, none exceeding 2 cm in diameter; 
regional lymph nodes are negative 
IIIc Peritoneal metastasis beyond the pelv is >2 cm in diameter and/or positive 
regional lymph nodes  
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Stage IV Growth involv ing one or both ovaries with distant metastases. I f 
pleural effusion is present, there must be positive cytology to allot a 
case to Stage IV. Parenchymal liver metastasis equals Stage IV 
  
Table 1 | Carcinoma of the ovary: FIGO nomenclature. Adapted from FIGO 
2009  
 
Borderline and low-grade ovarian cancers (Stage Ia, table 1): Cyto-
reductive surgery is generally recommended, but can be restricted to the 
affected ovary and corresponding fallopian tube to maintain fert ility in 
young women. Early and late stage ovarian cancers are managed by 
cytoreductive surgery and chemotherapy. Neoadjuvant chemotherapy is 
used regularly to reduce tumor volumes before surgery in advanced 
stages. Typical chemotherapy for ovarian cancers is carboplat in alone or 
carboplat in and paclitaxel and achieves clinical complete remission in the 
majority of patients. The poor 5-year survival rate of patients with 
advanced ovarian cancers of 68,1% (Stage I I I) and 29,1% (Stage IV) 
(American Cancer Society 2007) is due to high recurrent rates with 
progressive chemotherapy resistance, underlining the necessity for further 
research in biological t reatment strategies (Bookman 2010).  
Current  clinical research of t arget ed t herapies 
Angiogenesis is crucial for all solid tumors exceeding 1-2mm and vascular 
endothelial growth factor (VEGF) signaling is the most dominant pathway 
in new vessel formation promoting migrat ion, proliferat ion and survival of 
endothelial cells (Folkman 1971). High levels of VEGF are found in many 
ovarian tumors, sera and ascites (Boss et al 2001, Kraft et al 1999, Zebrowski 
et al 1999) and inhibit ion of VEGF signaling in animal models demonstrated 
reduction in ascit ic fluid accumulat ion, vessel formation and tumor growth 
(Byrne et al 2003). Bevacizumab binds human VEGF-A and is approved for 
t reatment of colorectal, renal, breast and non-small cell lung cancer and 
glioblastoma and showed high response rates in ovarian carcinomas in 
clinical t rials (Burger et al 2007, Cannistra et al 2007). Several small 
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molecule VEGF receptor inhibitors (Cediranib, Sorafenib, Vargatef, 
Pazopanib) are current ly invest igated in ovarian cancers (Matulonis et al 
2009, Rauh-Hain and Penson 2008). Some of these inhibitors target related 
classes of receptors. Vandetanib, a VEGFR/EGFR inhibitor is current ly 
tested in recurrent ovarian cancer besides several other ongoing or 
planned clinical t rials (Ledermann and Raja 2010). 
Epidermal growth factor (EGF) receptor overexpression is frequently found 
in ovarian cancers and nuclear expression is associated with a poor 
prognosis, but the relat ionship between overexpression and prognosis 
remains unclear (de Graeff et al 2009, Xia et al 2009). Many monoclonal 
ant ibodies (Trastuzumab, Cetuximab, Pertuzumab, Panitumumab) and 
small molecule inhibitors (Erlot inib, Gefit inib) have been invest igated in 
ovarian cancers. Overall, they show only modest activity as monotherapy 
and achieve only non-significant improvement of progression-free-survival 
in combination with chemotherapy. The response of a part icular patient to 
Gefit inib due to an EGFR mutation underlines the necessity for predict ive 
markers (Ledermann and Raja 2010). 
Src kinases are non-receptor tyrosine kinases involved in intracellular 
signaling. Overexpression is linked to a poor prognosis (Wiener et al 2003), 
inhibit ion of Src reverses chemoresistance in ovarian cancer cell lines 
(Chen et al 2005) and exhibits ant iangiogenic propert ies (Han et al 2006) 
suggest ing an attractive therapeutic target strategy for ovarian cancers. 
Poly-ADP-ribose polymerase (PARP) proteins fulfill diverse functions and are 
involved in DNA repair leading to accumulat ion of single-strand breaks at 
PARP inhibit ion (Hoeijmakers 2001) further result ing in double-strand breaks, 
which are normally corrected by BRCA-dependent homologous 
recombination. Cells carrying homozygous mutations in BRCA1 and BRCA2 
rely to the more error-prone and PARP-dependent non-homologous end 
joining pathway leading to chromosomal instability and malignancy 
(Farmer et al 2005) and are highly sensit ive to PARP inhibit ion (Ledermann 
20 
 
and Raja 2010). The PARP inhibitor Olaparib demonstrated dose-
dependent high response rates in BRCA1/BRCA2 mutation carriers (Fong 
et al 2009), but hypermethylat ion of BRCA1 is also found in 31% of 
sporadic, non-BRCA-mutant ovarian cancers indicating the general ut ility 
of PARP inhibitors in cancer cells with aberrat ions in the homologous 
recombination repair pathway (Ledermann and Raja 2010, McCabe et al 
2006). PARP inhibitors MK4827, AGO14699 and ABT888 are current ly being 
studied in early phases of clinical t rials (Ledermann and Raja 2010). 
α-folate receptor was found to be overexpressed in a range of tumor 
types and in 70% of primary and 82% of recurrent ovarian carcinomas 
while levels correlated with the stage of the tumor (Kalli et al 2008). 
Inhibit ion with monoclonal ant ibodies (Farletuzumab) demonstrated 
reduction in growth rates and cellular and complement -mediated toxicity 
and is current ly invest igated in a phase I I  clinical t rial (Ledermann and 
Raja 2010). 
Many novel molecular targets are being evaluated in the treatment of 
ovarian cancer and most of them demonstrate promising clinical activity. 
The wide range of newly available drugs underlines the necessity for 
reliably predict ive serum markers for the improvement of ovarian cancer 
therapy. 
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3.2 Fibroblast growth factor signaling 
 
3.2.1 Fibroblast growth factor receptors 
 
The fibroblast growth factor receptor family consists of four highly related 
members, FGFR-1, FGFR-2, FGFR-3 and FGFR-4 (Johnson and Williams 1993). 
In 2000, a fifth member (FGFR-5, FGFR-L1) was identified, which lacks the 
tyrosine kinase domain and is believed to be involved in negative 
regulat ion (Wiedemann and Trueb 2000). The amino acid sequences are 
highly conserved, but the receptors differ in ligand specifity and t issue 
distribut ion. FGF signaling is crucial for the development of almost all t issues 
and organs (Powers et al 2000) as well as homeostasis in adult  body t issues, 
leading to pathological condit ions, cell t ransformation and cancer when 
normal FGFR functions or expression levels are altered. FGF receptor 1-3 
gene knockouts are embryo-lethal due to failure in formation of the 
primit ive streak (Jaskoll et al 2002). The phenotype of activat ing FGF 
receptor mutations, which result  in abnormal activat ion or ligand 
independency are therefore the primary source of knowledge for their role 
in embryonic development. 
Fibroblast  growt h fact or recept or 1 
In the evolving embryo, FGFR-1 has a central role in the development of 
the nervous system and is involved in growth regulat ion of long bones.  
Loss-of-function mutations in FGFR-1 lead to a dysfunction of nerve cell 
migrat ion causing the “Kallmann syndrome”, which is characterized by 
anosmia and hypogonadotrophic hypogonadism. It  is st ill uncertain how 
FGFR-1 mutation leads to other varying symptoms of the “Kallmann 
syndrome”, like cleft palate or abnormal tooth development. Pfeiffer 
syndrome is associated with gain-of-function mutations in FGFR-1. 
Dysregulat ion of bone development leads to premature fusion of skull 
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bones (craniosynostosis) and cutaneous syndactyly (Chen and Deng 2005, 
Dode et al 2007, Pitteloud et al 2006). 
FGFR-1 expression is widespread over the human adult  organs. High levels 
were found in the skin, cornea, lung, heart and placenta, moderate levels 
in test is and ovary (Hughes 1997). 
Fibroblast  growt h fact or recept or 2 
FGFR-2 is involved in the regulat ion of bone growth and bone cell 
determination. Loss-of-function mutations in FGFR-2 lead to the lacrimo-
auriculo-dento-digital (LADD) syndrome which is characterized by 
abnormal development of lacrimul ducts and salivary glands, abnormally 
shaped ears, hearing loss, tooth abnormalit ies and malformations of hands 
and feet. Many syndromes for gain-of-function mutations of FGFR-2 have 
been described, including Apert, Beare-Stevenson, Crouzon, Jackson-
Weiss and Pfeiffer (table 2). They are characterized by premature fusion of 
skull bones (craniosynostosis) and limb abnormalit ies (Carinci et al 2005, 
Shams et al 2007, Wilkie 2005). 
Syndrome Craniosynostosis other characteristics 
Apert + bony syndactyly 
Beare-Stevenson + cutis gyrata 
Crouzon + 
graded severity of limb abnormalities 
(nil, broad first digits, elbow fusion) 
Jackson-Weiss + 
Pfeiffer + 
   
Table 2 | Syndromes caused by FGFR-2 gain-of-function mutations. (Wilkie 
2005) 
 
FGFR-2, similar to FGFR-1, is widely expressed in human adult  organs. 
Abundant expression was found in the prostate and stomach but not in 
pancreas, ovary, cornea and placent a (Hughes 1997).  
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Fibroblast  growt h fact or recept or 3 
FGFR-3 is involved in the regulat ion of ossificat ion by limit ing the 
transformation of cart ilage to bone cells. Abnormal receptor activity is 
often associated with skin disorders, indicating an important role in 
kerat inocyte development. Gain-of-function mutations show different 
phenotypes depending on the degree of FGFR-3 activat ion, but 
achondroplasia, premature skull bone fusion (“Muenke syndrome”) and 
thickened and/or dark skin are most common (Chen and Deng 2005, 
Coumoul and Deng 2003, Horton and Lunstrum 2002). 
FGFR-3 has a more restricted pattern of t issue-distribut ion. It  was found in 
the appendix, colon, liver, sublingual gland, placenta and cervix but not in 
the stomach, duodenum, ileum, kidney and ureter. It  is worth noting, that 
the overall immunoreactivity for FGFR-3 was much lower than for FGFR-1 
and FGFR-2 (Hughes 1997). 
Fibroblast  growt h fact or recept or 4 
FGFR-4 is involved in the maturat ion of limb muscles and skull bones. 
Foveal cones show high levels of FGFR-4 indicating an important role of 
FGFR-4 in development and maintenance of the ret ina. Knock-out mice 
are viable but show reduced limb muscles (Marics et al 2002) and 
elevated cholesterol metabolism (Yu et al 2000). 
FGFR-4 has a restricted pattern of expression in the human adult  body and 
is highly expressed in the liver, sublingual gland ducts, kidney, ureter and 
media of arterioles and veins of different organs including the ovaries 
(Hughes 1997). 
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3.2.2 Structure of fibroblast growth factor receptors 
 
 
 
Figure 1 | Domain structure of FGFR-1. Adapted from Groth and Lardelli 2002, 
sizes are not to scale. 
 
The general st ructure of FGF receptors is highly conserved (Johnson and 
Williams 1993). Figure 1 (Groth and Lardelli 2002) shows a schematic 
diagram of the domain structure of FGFR-1 as an example of the general 
FGF receptor structure. More detailed schematics of exon arrangements 
of FGF receptors 1-4 can be found in figures 9-12. 
Extracellular, there is a signal peptide followed by three immunglobuline- 
(Ig-) like domains. The acidic box, a heparin-binding and a cell adhesion 
molecule (CAM) homology domain (CHD) are located between IgI and 
IgII  (Green et al 1996). The transmembrane region is followed by a 
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juxtamembrane domain, a split  tyrosine-kinase domain and a short c-
terminal tail (Johnson and Williams 1993). 
Alt ernat ive splicing generates a great diversity of FGF receptor isoforms. 
The signal peptide is important for the transport of the receptor to the cell 
surface, indicating that isoforms lacking the signal peptide will stay in the 
cytosol or modulate transcript ion factor activity in the nucleus. The acidic 
box forms an autoinhibitory loop with the immunglobuline-like domain I 
and excision of one or the other during the alternative splicing process 
potentially leads to faster and/or prolonged response to ligand binding 
(Groth and Lardelli 2002, Olsen et al 2004). 
 
a 
 
 
 
 
Figure 2 | Alternative 
splicing of FGF receptors 
leads to different ligand- 
binding specifities. (Turner 
and Grose 2010) 
b 
 
 
Alternative splicing of the immunglobuline-like domain I I I  leads to the 
extensively studied isoforms “II Ia”, “I I Ib” and “II Ic” which do only exist  for 
the FGF receptors 1-3. I I Ia is composed of Ig-domain I I  and the first  half of 
Ig-domain I I I  (I I Ia, figure 2a). It  is therefore soluble and incapable to 
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activate downstream signaling, but has a high affinity for fibroblast growth 
factors indicating a regulatory mechanism. Isoforms I I Ib and I I Ic are 
generated by exon skipping result ing in different amino acid sequences in 
the second half of the immunglobuline-like domain I I I  (figure 2a) which 
leads to different ligand binding specifit ies (figure 2b). Isoforms lacking the 
transmembrane domain are soluble and may act in the cytoplasm as well 
as in the nucleus. FGF receptor variants without the split  tyrosine kinase 
domain are believed to act as negative regulators due to their capability 
to form dimers with active receptors (Johnson and Williams 1993, Turner 
and Grose 2010). 
Expression of fibroblast  growt h fact or recept or splice variant s 
Rubin et al 1989 were the first  to notice that kerat inocytes express 
receptors for FGF-7, but fibroblasts and endothelial cells do not. On the 
other hand, endothelial cells and fibroblasts do express receptors for 
FGF-2, which cannot be found on epithelial cells. Johnson et al 1991 
examined the expression of fibroblast growth factor receptor 1 splice 
variants in more detail and showed that variants I I Ia, I I Ib and I I Ic are 
expressed exclusively as well as simultaneously by different cell lines, but 
expression levels of variant I IIc always exceeded those of variant IIIb by far.  
Extensive in situ hybridizat ion analysis on t issue-specific expression of FGFR 
splice variants have been performed in rat (Wanaka et al 1991), chicken 
(Patstone et al 1993) and mouse embryos (Kornbluth et al 1988) and 
showed dist inct cell-type-specific spatial and temporal patterns of 
receptor expression during development. Unfortunately, there is very 
limited data of t issue-specific cell-distribut ion of part icular FGFR splice 
variants in normal human adult  t issues at protein level as it  was only 
evaluated in a small number of t issues without any cellular localizat ion and 
in most cases for FGF receptors 1 and 2 only (Hughes 1997). 
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Different splicing variants of FGF receptors 1-4 will be abbreviated as 
follows (table 3). 
 Receptor Abbreviation  
 FGFR-1 I I Ib 1b  
 FGFR-1 I I Ic 1c  
 FGFR-2 I I Ib 2b  
 FGFR-2 I I Ic 2c  
 FGFR-3 I I Ib 3b  
 FGFR-3 I I Ic 3c  
 FGFR-4 4Δ  
    
Table 3 | Abbreviations for FGF receptors 1-4 
 
3.2.3 Fibroblast growth factors 
 
22 fibroblast growth factors have been identified and are clustered into 7 
subfamilies due to their sequence similarit ies and functional propert ies. 
Their evolut ionary relat ionship is illustrated as a phylogenetic tree shown in 
figure 3 (Itoh and Ornitz 2004). 
 
 
Figure 3 | Evolutionary 
relationship of human 
fibroblast growth factors. 
FGFs are div ided into 7 
subfamilies, each with 2-4 
members due to sequence 
similarities and functional 
properties. Branch lengths 
represent evolutionary 
distances between the 
genes. Adapted from I toh 
and Ornitz 2004. 
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Although they share a high sequence similarity, the members of the FGF-11 
subfamily are not able to activate FGF receptors. They were renamed to 
fibroblast homologous factors (FHF) and are not generally considered 
members of the FGF family (Olsen et al 2003). FGF-15 is the murine 
paralogue of human FGF-19 and therefore not shown in figure 3. 
3.2.4 FGF-FGFR signaling system 
 
All FGFs except FGF-1, FGF-2 and the FGF-9 subfamily have a signal 
peptide determining their secret ion. FGF-1 and FGF-2 are secreted via a 
direct protein export mechanism (Nickel 2005), while the FGF-9 subfamily is 
sequestered through the endoplasmatic ret iculum and the subsequent 
Golgi pathway (Revest et al 2000). 
In order to bind to FGF receptors, FGFs need heparin sulphate 
proteoglycans (HPSG). A functional FGF-FGFR unit  consists of 2:1:2 
FGF:HPSG:FGFR subunits as shown in figure 4. 
 
 
Figure 4 | Basic structure of the 
FGF:HPSG:FGFR complex. A functional 
FGF-FGFR unit consists of 2:1:2 
FGF:HPSG:FGFR subunits. Adapted 
from Turner and Grose 2010. 
 
Beside HPSG availability, FGF signaling is regulated through various 
mechanisms. As described before and shown in table 4, FGF receptors 
have different  ligand-binding propert ies. This is among others due to 
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alternative splicing in the IgII I -domain. Autocrine signaling is prevented by 
t issue-specific expression patterns of FGFs and FGF receptors. Generally, 
epithelial-like cells tend to express I I Ib-variants, while mesenchymal-
associated cells do express I I Ic-variants (Johnson and Williams 1993).  
 
 
Table 4 | Relative activity of fibroblast growth factors. FGFs are arranged by 
subfamily identity. FGF-11 subfamily corresponds to fibroblast homologous 
factors. FGF-19 subfamily’s activ ity is weak due to its dependence on Klotho-
proteins. Abbreviations are explained in table 3. Adapted from Zhang et al 2006. 
 
Zhang et al 2006 were not able to find any significant activat ion of FGF 
receptors by the FGF-19 subfamily. This is due to their dependence on 
Klotho-proteins which enhance FGF receptor binding and are expressed in 
a t issue-dependent manner (Kurosu et al 2006). It  turned out that FGF-19, 
FGF-21 and FGF-23 act in an endocrine instead of a paracrine manner 
(Beenken and Mohammadi 2009). 
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3.2.5 FGF receptor downstream signaling 
 
Fibroblast growth factor receptors act as dimers in a ligand dependent 
manner. Activat ion and subsequent dimerizat ion of the receptors leads to 
transphosphorylat ion of tyrosine-kinase domains and the c-terminus, which 
act as docking sites for adaptor proteins and results in activat ion of 
mult iple signaling pathways as shown in figure 5 (Turner and Grose 2010). 
 
Figure 5 | FGFR signaling network. Signaling pathways are described in the text. 
Abbreviations: FGF, fibroblast growth factor, FGFR, fibroblast growth factor 
receptor, SEF, similar expression to fgf genes, FGFRL1, FGFR-like 1, FRS2α, FGFR 
substrate 2α, GRB2, growth factor receptor bound protein 2, SOS, son of 
sevenless, SPRY, Sprouty, GAB1, GRB-associated-binding protein 1, PI3K, 
phosphoinositide 3-kinase, MEK, MAP/ERK kinase, MAPK, mitogen activated 
protein kinase, MKP3, MAPK phosphatase 3, MKP1, MAPK phosphatase 1, AKT, 
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protein kinase B, STATs, signal transducers and activators of transcription, PIP2, 
phosphatidylinositol 4,5-bisphosphate, PLCγ, phosphoinositide phospholipase C, 
DAG, diacylglycerol, PKC, protein kinase C, IP3, inositol triphosphate, FOS, FBJ 
murine osteosarcoma v iral oncogene homolog, JUN, jun proto-oncogene, PEA3, 
polyoma enhancer activator 3. Turner and Grose 2010. 
 
FGFR substrate 2 (FRS2) is a key adaptor protein of FGF signaling and 
most ly specific to FGF receptors (Gotoh 2008). It  binds to the 
juxtamembrane domain of the FGF receptor and is phosphorylated at 
mult iple sites upon activat ion. The following recruitment of SOS and GRB2 
activates Ras, Raf and the MAPK signaling pathway (Eswarakumar et al 
2005), which is activated primarily in response to FGF treatment and leads 
to cell proliferat ion in the majority of t issues. PI3K pathway and AKT 
signaling is activated independent ly of SOS through GAB1 (Altomare and 
Testa 2005) and generally promotes anti-apoptotic mechanisms. 
PLCγ is t riggered independent ly of FRS2 and activates PKC, which can 
directly interact with Raf, activat ing MAPK pathway (Klint and Claesson-
Welsh 1999). Other activated pathways are p38 MAPK, Jun kinase, STATs 
and RSK2 depending on the cellular context (Kang et al 2009). 
Negative regulat ion of FGF signaling is insufficient ly studied yet. Activated 
receptors are internalized and degraded or recycled. FRS2 is 
phosphorylated at Threonine and Serine residues leading to inhibit ion of 
GRB2-binding (Gotoh 2008). SPRY, SEF, MAPKP3 and MKP1 modulate 
downstream signaling at different points of the signaling cascade. 
 
3.2.6 Aberrant FGF signaling and cancer 
 
Act ivating mutat ions. Somatic mutations of FGFR-3 can be found in about  
half of all bladder cancers (Cappellen et al 1999). A single mutation in the 
extracellular domain of FGFR-3 (S249C) leads to const itut ive 
homodimerizat ion and subsequent activat ion of the receptor and 
corresponds to 50% of all mutations in FGFR-3 (di Mart ino et al 2009, Naski 
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et al 1996). Activat ing mutations identified in cancer cells frequently 
exhibit  the same nucleotide aberrat ions as seen in skeletal dysplasias 
(Ornitz and Marie 2002). 
Gene amplificat ions are common in FGFR-1 and FGFR-2 but not in FGFR-3 
(Nord et al 2010). 10% of gastric cancers show an amplification of FGFR-2 
and are highly sensit ive to FGFR inhibit ion (Kunii et al 2008, Takeda et al 
2007). 10% of all breast cancers show amplification of FGFR-1. 
Chromosomal t ranslocat ions are found in 15% of mult iple myelomas and 
these cells are highly sensit ive to FGFR inhibit ion (Qing et al 2009, Trudel et 
al 2006). Many translocations in FGF receptors have been identified and 
normally show a fusion of a transcript ion factor with the tyrosine-kinase 
domain of the receptor leading to const itutive dimerizat ion and activation 
of FGF downstream effectors (Roumiantsev et al 2004, Xiao et al 1998, 
Yagasaki et al 2001). 
Aut ocrine/Paracrine signaling. Melanomas express high levels of FGFR-1 
and FGF-2 and inhibit ion leads to growth regression in human melanoma 
xenografts, suggest ing an autocrine signaling loop (Wang and Becker 
1997). FGF-1 is frequently amplified in ovarian cancers which could 
promote angiogenesis (Birrer et al 2007). Addit ionally, an autocrine FGF-
2/FGFR-1II Ic signaling loop was identified in non-small cell lung cancer 
(Marek et al 2009). Paracrine signaling is difficult  to model, but several FGFs 
have been found to be overexpressed in various cancer types (Poon et al 
2001). 
Increased signaling in prostate cancer cells was found due to loss of 
expression of negat ive regulat ors (SPRTY (Fritzsche et al 2006), SEF (Darby 
et al 2006)) and is believed to promote androgen-independency (Kwabi-
Addo et al 2004). 
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3.2.7 Carcinogenic mechanisms of aberrant FGF signaling 
 
Proliferat ion. Enhanced proliferat ion is one important characterist ic of 
cancer cells. Mouse models have shown that overexpression of FGF-10 
and FGF-8 in the murine prostate promotes epithelial hyperproliferat ion, 
but a second mutation (AKT and PTEN, respectively) was necessary to 
induce tumorigenesis (Abate-Shen and Shen 2007, Memarzadeh et al 
2007). 
Survival. Depending on the cellular context, FGFs can trigger activat ion of 
ant i-apoptotic pathways (PI3K, STAT). High FGF-2 serum-levels are 
associated with poor prognosis in small cell lung cancer (SCLC), which is 
due to upregulat ion of ant i-apoptotic proteins (Pardo et al 2002, Pardo et 
al 2006). 
Migrat ion, Invasion. A const itut ively active FGFR-1 was shown to induce 
invasive mammary lesions (Welm et al 2002) and prostat ic intraepithelial 
neoplasia (Freeman et al 2003). FGFR-2II Ib – FGF-10 dependent invasion 
was found in pancreatic cancer cells (Nomura et al 2008). 
Angiogenesis. FGF signaling comprises a key function in epithelial repair 
and FGF-2 possesses an essential role in blood vessel formation at the 
wound site (Werner and Grose 2003). Various FGFs were shown to be 
involved in tumor angiogenesis (Kandel et al 1991, Presta et al 2005). They 
st imulate vessel formation and maturat ion, facilitate degradation of 
extracellular matrix (ECM) and alter intercellular adhesion and 
communication (Presta et al 2005). FGF-1 is regularly upregulated in 
ovarian cancer cells (Birrer et al 2007) and release of FGF-2 from tumor 
cells acting on endothelial cells has been described previously 
(Schweigerer et al 1987). 
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3.2.8 Inhibition of FGF signaling 
 
 
Table 5 | FGF receptor inhibitors. Adapted from Turner and Grose 2010 
All FGF receptor tyrosine kinase inhibitors are ATP-competit ive and also 
target VEGFR-2 due to their st ructural similarity. Targeting FGFR as well as 
VEGFR has striking advantages, inhibit ing proliferat ion and angiogenesis 
simultaneously. In contrast , mult i-kinase inhibitors are not very potent 
against FGF receptors and achieving sufficient inhibit ion might be 
challenging (Turner and Grose 2010). Table 5 gives an overview on FGF 
receptor inhibitors. One major side-effect of FGF receptor inhibit ion is 
hyperphosphatemia by blocking FGF-23 signaling, which is the key 
regulator of phosphate homeostasis (Shimada et al 2004). Antibodies 
exhibit  ant iproliferat ive effects in bladder cancer cells and t(4;14) 
myeloma (Qing et al 2009). FGF-7 is licensed for t reatment of mucosit is 
induced by myelotoxic therapy (Turner and Grose 2010). 
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PD173074, a small molecule inhibitor, originally published as an FGFR-1 and 
VEGFR-2 inhibitor (Mohammadi et al 1998) was later shown to inhibit  FGF 
receptors 1-3 vigorously and FGFR-4 at high doses (Ezzat et al 2005). It  
reversibly binds to the receptor tyrosine kinase (RTK) ATP cleft and inhibits 
autophosphorylat ion of the dimerized receptors. Although it  was shown, 
that PD173074 inhibits survival and growth in FGFR-dependent cancer cells 
(Byron et al 2008, Kunii et al 2008, Trudel et al 2004), it  was dropped from 
clinical t rials due to toxicity issues and is now being used as a research 
tool. 
CHIR-258 (TKI258, Dovit inib) is a mult i-kinase inhibitor targeting RTK-classes III 
(platelet derived growth factor receptor, PDGFR), IV (FGFR) and V 
(vascular endothelial growth factor receptor, VEGFR). It  is current ly in 
phase I I  of clinical development. Recent analyses with Kinomescan, a 
competit ion binding assay, indicate that CHIR-258 is much more 
promiscuous and that FGFR-2 is inhibited too. Nonetheless, FGFR-4 is poorly 
affected by CHIR-258 (Karaman et al 2008). 
 
Receptor IC50, µM  Receptor IC50, µM 
FLT3 0,001  PDGFR-ß 0,027 
c-KIT 0,002  PDGFR-α 0,21 
CSF-1R/c-fms 0,036  InsR 2 
FGFR-1 0,008  EGFR-1 2 
FGFR-3 0,009  c-Met >3 
VEGFR-1 0,01  EphA2 4 
VEGFR-2 0,013  Tie2 4 
VEGFR-3 0,008    
Table 6 | CHIR-258 in-vitro kinase assay (Trudel et al 2005) 
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4 Materials and Methods 
 
Human cell lines 
Human ovarian cancer cell lines, SV-40 immortalized ovarian surface 
epithelium and primary ovarian surface epithelium. Citat ions refer to the 
first  announcement in literature if the isolat ion of the cells was not 
published independently. 
 
Cell line Description isolation site Reference 
  
  
A-2774 
adenocarcinoma 
unknown (Vigani et al 1990) 
A-2780 ascites (Eva et al 1982) 
CAOV-3 unknown (DiSaia et al 1975) 
H-134 ascites (Broxterman et al 1987) 
HEY primary (Buick et al 1985) 
HOC-7 ascites (Buick et al 1985) 
OVCAR-3 ascites (Hamilton et al 1983) 
SKOV-3 ascites (DiSaia et al 1975) 
TR-170 ascites (Hill et al 1987) 
PA-1 teratocarcinoma primary (Giovanella et al 1974) 
IOSE-80 SV-40 immortalized 
ovarian 
surface epithelium 
primary (Maines-Bandiera et al 1992) 
IOSE-364 primary (Maines-Bandiera et al 1992) 
IOSE-386 primary (Maines-Bandiera et al 1992) 
OSE 
primary ovarian 
surface epithelium 
primary Innoprot, Derio, Spain 
 
Growt h media of cell lines 
Cell line growth medium (GM) freezing medium 
  
 
A-2774 αMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
A-2780 RPMI +10% FCS +1% PSG GM +5% FCS +10% DMSO 
CAOV-3 αMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
H-134 αMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
HEY DMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
HOC-7 αMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
OVCAR-3 αMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
SKOV-3 αMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
TR-170 DMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
PA-1 αMEM +10% FCS +1% PSG GM +5% FCS +10% DMSO 
IOSE-80 
Medium 199/MCDB 105 (1:1) +5% FCS 
+1%PSG 
GM +35% FCS +6% DMSO 
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IOSE-364 
Medium 199/MCDB 105 (1:1) +5% FCS 
+1%PSG 
GM +35% FCS +6% DMSO 
IOSE-386 
Medium 199/MCDB 105 (1:1) +5% FCS 
+1%PSG 
GM +35% FCS +6% DMSO 
OSE 
Basal medium +5ml OEpiCGS +5ml PS-
solution 
GM +15% FCS + 10% DMSO 
 
Thawing of cells 
The cryotube containing cells of interest was thawed in aqua bidest at 
room temperature and transferred to 20ml precooled growth medium. 
After centrifugation for 5 min at 4°C, 1000rpm, the supernatant  was 
decanted and the cell pellet reconst ituted in 14ml growth medium at 
room temperature. The obtained cell suspension was split  up into two T25 
t issue culture flasks and incubated as described below. 
 
Maint enance of cell cult ure 
All cell lines were cultured in T25 t issue culture flasks in 7ml of the respective 
growth medium (see table above), incubated at 37°C, 5% CO2, 95% 
humidity and passaged when confluence reached 80-90% (preferably 
once a week). Cells were carefully washed with Dulbecco’s PBS (D-PBS), 
800µl Trypsin/EDTA was added and the flask was incubated at 37°C until 
cells detached. After tapping the flask gently, the cells were diluted in 
accordance to their growth rate in two T25 t issue culture flasks containing 
growth medium and were incubated as described. 
Cryopreservat ion of cells 
Cells were grown in growth medium containing 10% FCS unt il they 
reached 70-80% confluence and were harvested by trypsinizat ion and 
centrifugation (5min at 1000rpm). After resuspending in freezing medium, 
cells were counted (Neubauer chamber, cells diluted 1:10 in t rypan blue) 
and a suspension containing twice as much the final cell concentrat ion 
was prepared. Cryogenic tubes were placed on ice, 500µl of the 
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prepared cell suspension was added to every vial and left on ice for 
15min. After 500µl of precooled freeze medium containing 12% or 20% 
DMSO, respectively, were added and mixed gently, the suspension was 
left on ice for 30min. Vials were put into “Mr. Frosty” freezing container 
(Fisher Scient ific, Rochester NY) overnight at -80°C and transferred to liquid 
nit rogen the next day. 
 
Cell proliferation and cytotoxicity assay 
Solut ions 
Paraformaldehyde solut ion. 0,4g Paraformaldehyde was added to 10ml 
DPBS. Solut ion was heated in a fume hood while taking care that it  did not 
exceed 60°C. After all solid part icles were dissolved, 5N NaOH was added 
until the solut ion cleared ( 2µl). Finally, the solut ion was filter sterilized, 
aliquoted and stored at -20°C. 
Destaining solut ion. 10% acetic acid, 25% methanol in aqua bidest  
Crystal violet solut ion. 0,5% crystal violet, 25% methanol in aqua bidest  
 
Cells were grown in growth medium containing 10% FCS unt il they 
reached 70-80% confluence and harvested by trypsinizat ion and 
centrifugation (5min at 1000rpm). After resuspending in growth medium 
containing 5% FCS, cells were counted (Neubauer chamber, cells diluted 
1:10 in t ryphan blue), the desired concentrat ion was prepared and the 
cells seeded in a 96-well plate using a Dispenser Mult ipette. After 
incubation overnight, growth medium was removed and 100µl growth 
medium containing twice as much the desired final FCS concentrat ion 
was added. A dilut ion series was prepared in growth medium containing 
0% FCS with twice as much the desired final concentrat ion of the 
substance of interest and added to the wells in t riplicates. Note: Care was 
taken to ensure consistent amounts of solvent (e.g. DMSO) when the 
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substance of interest was not solubilized in water.    d     
Cell number was determined after 72 hours using paraformaldehyde-
fixat ion with crystal violet staining as described below. 
Fixat ion / Cryst al violet  st aining 
Medium was removed and cells were washed with cold D-PBS. 50µl of 
paraformaldehyde solut ion were added and cells were incubated for 
30min at room temperature. After washing with cold DPBS, 50µl of crystal 
violet solut ion were added and incubated for 10min at room temperature. 
Subsequently, cells were washed three t imes with aqua bidest and plates 
were allowed to dry for at least two hours or overnight. 
Det ect ion  
100µl of destaining solut ion were added and incubated for 20min at room 
temperature. Optical density was determined using a micro-plate reader 
(absorbance 570nm/reference 405nm). 
 
Scratch-assay (adapted from Liang et al 2007) 
Cells were seeded in 35mm dishes with different cell numbers to create a 
confluent monolayer (A-2780: 4,7∙106, HEY: 1,5∙106, SKOV-3: 7,5∙105. 
OVCAR-3 cells do not adhere when seeded at high densit ies) in 3ml 
medium containing 5% FCS and allowed to adhere overnight. 
Next day, the cell monolayer was evenly scratched 
using a yellow pipette t ip (a). Growth medium was 
removed and cells were washed with 1ml D-PBS 
and 1ml growth medium. Treatment was 
performed in 2ml medium. 
Dishes were marked with 6 scratches in the plast ic 
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bottom (b1-b6) perpendicular to the scratch in the cell monolayer (a) with 
a sharp scalpel. The start ing point for the measurement was marked too 
(c). 
Measurement was done using an eyepiece 
micrometer at 10x optical magnification: For each 
measuring point b1-b6, the scratch in the bottom 
of the plate was focused first  and posit ioned 
coincidentally to the scale of the micrometer. 
Then, without moving the dish, the cell layer was focused and the distance 
between the margins of the monolayer (m1, m2), which is equal to the 
width of the scratch (a) was noted at 0-2-4-6-8-24 hours after scratching 
the cell monolayer. 
Analysis of data: For normalizat ion of cell migrat ion data, the width of 
each scratch at the “0 hour” t ime-point was subtracted from the 
corresponding “2, 4, 6, 8, 24 hours” t ime-points. For each t ime-point, the 
mean value and the standard deviat ion was calculated from the 6 
individual measurements per t ime point. 
 
Western Blot Analysis 
Solut ions 
 
Reagent 
Stock 
conc. 
Quantity 
Final 
conc. 
     
RIPA NaCl 5M 3ml 150mM 
 Tris pH7,4 1M 5ml 50mM 
 DOC (Sodium deoxycholate) 10% 5ml 0,5% 
 EGTA 50mM 4ml 2mM 
 EDTA, pH7,4 50mM 10ml 5mM 
 NaF 500mM 6ml 30mM 
 ß-Glycerophosphate pH7,2 400mM 10ml 40mM 
 Tetrasodium pyrophosphate 100mM 10ml 10mM 
 Benzamidine 30mM 10ml 3mM 
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 Nonidet P-40 pure 1ml 1% 
 
adjust pH to 7,4 and fill up with aqua bidest to 95ml. Store at 
4°C. 
     
RIPA+ 1,9ml RIPA 
 20µl 200mM Na-Orthovanadate (heat-activated) 
 80µl 25x Complete stock solution (Roche, Boston MA) 
 
 Reagent 
Stock 
conc. 
Quantity 
Final 
conc. 
     
4x Sample buffer Glycerol pure 5ml 50% 
 Tris-HCl pH6,8 1M 1,25ml 125mM 
 SDS 20% 2ml 4% 
 Bromophenol blue 1% 1,25ml 0,125% 
 ß-Mercaptoethanol* pure 0,5ml 5% 
 total  10ml  
 *to be added just before use 
     
10x running buffer Tris base pure 30,3g 25mM 
 Glycine pure 144,2g 192mM 
 SDS pure 10g 0,1% 
 fill up with aqua bidest to 1000ml, store at 4°C 
     
1x TB Glycine pure 16,8g 150mM 
 Tris pH8,3 1M 75ml 50mM 
 SDS 10% 7,5ml 0,05% 
 Methanol pure 300ml 20% 
 Aqua bidest  1117,5ml  
 total  1500ml  
     
10x TBS Tris pH7,5 1M 500ml 50mM 
 NaCl 5M 300ml 150mM 
 Aqua bidest  200ml  
 1x TBS: add 900ml aqua bidest to 100ml 10x TBS (final 
concentration for 1xTBS) 
  
1x TBS-T TBS 10x 100ml 1x 
 Tween20 pure 1ml 0,1% 
 Aqua bidest  900ml  
     
10x BS TBST 1x 100ml 1x 
 BSA pure 4g 4% 
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Reagent Quantity Volume 
Final 
conc. 
     
Antibody solution TBS-T 1,053x 14,25ml 1x 
(first antibody) Blocking Solution 4,21% 4,75ml 4% 
 Sodium azide 
solution 
1% 1ml 0,05% 
 total  20ml  
     
Antibody solution TBS-T 1x 30ml 1x 
(second antibody) BS 4% 10ml 1% 
 total  40ml  
     
A/B solution Acrylamide 40% 7,4ml 30% 
 Bis Solution 2% 2ml 0,4% 
 Aqua bidest  0,6ml  
     
4% stacking gel A/B solution 30%/0,4% 1,673ml  
 Tris pH6,8 0,5M 3,15  
 SDS 10% 125µl  
 APS 10% 125µl  
 TEMED pure 12,5µl  
 Aqua bidest  7,46ml  
     
10% running gel A/B solution 30%/0,4% 6,7ml  
 Tris pH8,8 1,5M 5ml  
 SDS 10% 200µl  
 APS 10% 100µl  
 TEMED pure 10µl  
     
10% APS 
Ammonium 
persulfate 
pure 0,1g 
 
 Aqua bidest  1ml  
     
Antibodies Target protein Prov ider Catalogue no. 
    
 Actin Santa Cruz sc-1616 
 pFRS2Y196 Cell Signaling 3864S 
 pFRS2Y436 Cell Signaling 3861S 
 FRS2 Abnova H00010818-B01 
 p-AKTS473 Cell Signaling 9271S 
 AKT Cell Signaling 9272 
 p-ERK1/2 Cell Signaling 9101 
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 ERK1/2 Cell Signaling 9102 
 p-S6 Cell Signaling 2215 
 S6 Cell Signaling 2317 
 α-Rabbit (Donkey), 
HRP 
Promega V7951 
 α-Mouse 
(Chicken), HRP 
Santa Cruz sc-2954 
 
Medium was removed and cells were washed twice with cold D-PBS. After 
removing D-PBS completely, 100µl RIPA+ was added, the dish was left on 
ice for at least  5min and the cells were scraped using a cell scraper. The 
cell lysate was transferred to a microtube and left on ice for at least 10min 
while being vortexed regularly. Samples were centrifuged for 30min at 4°C, 
12500rpm and the supernatant was transferred to a fresh microtube and 
stored at -80°C. 
Prot ein concent rat ion was determined using Biorad Protein Assay 
Standard I I , BSA (10-0,156mg/ml) was used as a reference. 5µl of 
RIPA+/BSA dilut ion/sample was mixed with 20µl Reagent A’ (1ml Reagent 
A +20µl Reagent S) and 200µl Reagent B and incubated at room 
temperature (RT) for 20min, optical density was determined using a micro-
plate reader (absorbance 655nm/reference 450nm). Samples were 
adjusted to 1µg/µl in 1x sample buffer and stored at -20°C. 
SDS-PAGE: Protein samples in 1x sample buffer were boiled for 10min at 
95°C and vortexed. Thirty µl of those lysates were then applied to a 4% 
stacking/10% separation SDS-polyacrylamide gel. 2µl of the molecular 
weight marker “Magic Mark XP” (Invit rogen, Carlsbad CA) were loaded in 
parallel for est imation of molecular mass separation within the gel. 
Separating condit ions were 100V constant for about 2 hours in a Biorad 
Minigel Electrophoresis Chamber. 
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Prot ein t ransfer: Separated proteins were transferred to a methanol-
activated PVDF membrane using a Biorad Mini Transblot Module. Transfer 
condit ions were 290mA constant at 4°C overnight. 
Immunost aining: Membranes were blocked in blocking solut ion +4% FCS 
for 1h at RT on a shaker, washed 3 t imes, 5min each in TBS-T and 
incubated overnight with 10ml of the first  ant ibody at 4°C on a shaker. First  
ant ibody was saved, membranes washed 3 t imes, 5min each in TBS-T, 
incubated with the second antibody for 1h at RT on a shaker and finally 
washed 4 t imes (2x5min, 2x10min) with TBS-T and 4 t imes (2x5min, 2x10min) 
with TBS. 
Det ect ion: Protein bands were visualized by chemiluminescent detection 
through horseradish peroxidase conjugated to the secondary antibody. 
2,5ml Detection Solut ion 1 and 2,5ml Detection Solut ion 2 (ECL-Substrate) 
were added to the membrane and incubated for 5min on a shaker. 
Autoradiography films were exposed to the membrane for different t imes 
and developed with a Canon table developer. 
 
RNA-Isolation 
Cells were grown in growth medium containing 10% FCS in a T25 t issue 
culture flask. 
Homogenizat ion: Medium was completely removed and cells were 
incubated with 3ml of TRI Reagent (Sigma-Aldrich, St . Louis MO) for at least 
5min at RT while shaking the flask vigorously. Cell lysate was homogenized, 
t ransferred into a microtube and stored at -80°C. 
RNA-Ext ract ion/Precipit at ion: 150µl of cold bromo chloropropane (BCP) 
were added per sample, vortexed for 15sec, left at RT for 15min and 
centrifuged 15min at 4°C, 12500rpm. The aqueous phase was transferred 
into a new microtube; 1ml of isopropanol was added per sample, 
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vortexed for 15sec and centrifuged 10min at 4°C, 12500rpm. The 
supernatant was aspirated, 1,5ml 75% EtOH were added, vortexed for 
15sec and centrifuged 10min at 4°C, 12500rpm. The supernatant was 
aspirated again and the remaining RNA pellet was air-dried. Finally, RNA 
was dissolved in 20µl DEPC-treated water and stored at -80°C. 
Quant ificat ion and qualit y cont rol of RNA:  RNA was quantified 
spectrophotometrically measuring a 1:500 diluted sample against aqua 
bidest at 260/280nm twice in a quartz cuvette. Calculat ion of RNA -
concentrat ion: OD260 x 40 = µg/µl. Est imation of purity: 260/280 rat io ≥ 1,5. 
Quality/integrity of RNA was determined by agarose gel electrophoresis. 
0,3g agarose in 30ml 1xTAE (40mM Tris-acetate, 1mM EDTA in aqua bidest) 
were heated for 40 seconds in a microwave oven. After adding 3µl of Gel 
Red (Biot ium, Hayward CA), the fluid was poured into the assembled 
electrophoresis chamber. When the gel had polymerized, 250ml 1xTAE 
were added. Subsequently, prepared samples (0,5µl RNA in 12µl aqua 
bidest and 3µl 5x gel loading solut ion) were applied and separated using 
70V/210mA for 30 to 45min. RNA was photographed using a Herolab gel 
documentation system and checked for a clear appearance of the 
18S/28S ribosomal RNA bands. 
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cDNA-Synthesis 
Quantitated RNA was diluted to 0,2µg/µl. 
Mast ermix 
 Vol./sample (µl) Final conc. 
5x reaction buffer (250mM Tris-HCl pH8,3, 
375mM KCL, 15mM Mg2Cl2) 
4 1x 
DTT (100mM) 2 10mM 
BSA (RNAse/DNAse free), 2,9mg/ml 1 0,28mg/ml 
Protector RNAse Inhibitor (40U/µl) 0,315 0,62U 
DEPC-treated water 0,185  
dNTP Mix 100mM 0,8 7,8mM 
Random hexamer primers (100µM) 1 5µM 
200 UM-MLV reverse transcriptase (200U/µl) 1 10U 
total 10,3  
 
10µl RNA (0,2µg/µl) were added to 10,3µl Mastermix and incubated for 
60min at 37°C. cDNA and diluted RNA were stored at -80°C. 
 
Polymerase Chain Reaction 
GoTaq Green Master Mix (Promega, Madison WI) in a 25µl reaction 
volume was used for all PCRs. 
Mast ermix    
 Vol./sample (µl) Final conc. 
GoTaq Green Master Mix 12,5 1x 
Forward primer 1 0,8µM 
Reverse primer 1 0,8µM 
PCR water 9,5 0,62U 
cDNA 1  
total 25  
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PCR programs 
    
Program 
name 
annealing 
temp. (°C) 
cycles 
Hot start 95°C, algorithm 
measurement  
50anneal 50 30 
51anneal 51 30 
    52anneal 52 30 
1x 1’ 95°C  53anneal 53 30 
cycle 30’’ 95°C  56anneal 56 30 
 30’’ annealing temp.  60anneal 60 30 
 1’ 72°C  56a40c 56 40 
1x 7’ 72°C  57a45c 57 45 
1x ∞ 4°C  45a45c 45 45 
    56a45c 56 45 
    61a40c 61 40 
    60a40c 60 40 
    60a45c 60 45 
    54a40c 54 40 
    53a35c 53 35 
    63a40c 63 40 
    65a40c 65 40 
 
Primer sequences 
Name Sequence PCR program Reference Target 
 
FGF1s GAAGCCCAAACTCCTCTACTG 57a45c 
Fischer et al 
2008 
FGF1 
FGF1as TGTTGTAATGGTTCTCCTCCA 
FGF2s CTGTACTGCAAAAACGGG 45a45c FGF2 
FGF2as AAAGTATAGCTTTCTGCC 
FGF3s CCTAATCTGGCTGCTACTG 53anneal Self-made 
self-made 
FGF3 
FGF3as CCTCCACTGCCGTTATCTC 
FGF4s ACTACCTGCTGGGCATCAAGCG
G 
56a45c 
Fischer et al 
2008 
FGF4 
FGF4as TCTTGCTCAGGGCGATGAACATG
C FGF5s CCCGGATGGCMAGTCAATGG 61a40c FGF5 
FGF5as TTCAGGGCAACATACCACTCCC
G FGF6s AACGTGGGCATCGGCTTTCACCT
CC 
56a40c FGF6 
FGF6as CGCTTTACCCGTCATTTGC 
FGF7s CTTTGCTCTACAGATCATGCTTTC 60a40c FGF7 
FGF7as TTGCCATAGGAAGMAGTGGGCT
G FGF8s TGAGCTGCCTGCTGTTGCACTTG 60a40c FGF8 
FGF8as CTTGGCGATCAGCTTCCCCTTCTT
G FGF9s AATGTGCCCGTGTTGCCGGTG 56a40c FGF9 
FGF9as AATTTTCTGGTGCCGTTTAGTCCTA
GTCCCT FGF10s CCAAGAAGGAGAACTGCC 54a40c FGF10 
FGF10as CCATTCAATGCCACATAC 
48 
 
FGF16s ATCTACACGGCTTCTCCTC 50anneal Self-made 
self-made 
FGF16 
FGF16as TCTCCTCGCTCATTCATTC 
FGF17s TGCTGCCCAACCTCACTC 53a35c 
Fischer et al 
2008 
FGF17 
FGF17as TCTTTGCTCTTCCCGCTG 
FGF18s ACTTGCCTGTGTTTACACTTCC 53a35c FGF18 
FGF18as CCAGAACCTTCTCGATGAAC 
FGF19s CGGATCTCCTCCTCGAAAG 60a45c FGF19 
FGF19as GTGTGGTGGTCCACGTATG 
FGF20s ACAGCCTCTTCGGTATCT 56a40c FGF20 
FGF20as GGATCCACTGGTCTAGGTAA 
FGF21s TTCTGTGCTGGCTGGTCTT 56a40c FGF21 
FGF21as CACAGGAACCTGGATGTCTTG 
FGF22s CCTCTTCTCCTCCACTCACTTC 50anneal 
Self-made 
FGF22 
FGF22as TGCTTTGATGACCACGAC 
FGF23s CTGGCTTTGTGGTGATTA 50anneal FGF23 
FGF23as GGAAGTGATACTGAGGAGAG 
 
 
 
    
GAPDHs GAGAACGGGAAGCTTGTCAT 51anneal Grunt et al 
2005 
GAPDH 
GAPDHas TTCAGCTCAGGGATGACCTT 
 
FR5 TCCAGTGGCTAAAGCACATC  
Fischer et al 
2008 
 
FR7 CCGCATCCGAGCTATTAATC FR5-FR7 FGFR-1b 
  52anneal   
FR8 CGCCAAGCACGTATACTC FR5-FR8 FGFR-1c 
  50anneal   
FR11 AACGGGAAGGAGTTTAAGCAG   
FR12 TGGCAGAACTGTCAACCATGC FR11-FR12 FGFR-2c 
  52anneal   
FR13 CTCGGTCACATTGAACAGAG FR11-FR13 FGFR-2b 
  51anneal   
FR17
a 
AACGGCAGGGAGTTCCGCGGC   
FR19 CCCGTCCCGCTCCGACACATTG FR17a-FR19 FGFR-3b 
  60anneal  
FR20 CCCGGCGTCCTCAAAGGTG FR17a-FR20 FGFR-3c 
  56anneal   
FR25 GATGGACAGGCCTTTCATGG   
FR26 TGCTGCGGTCCATGTGGGGTCCTC FR25-FR26 FGFR-4 
  52anneal   
 
Self-designed primers were checked for secondary structures using 
NetPrimer (Premier Biosoft Int ., Palo Alto CA). TM was calculated by the 
nearest neighbour analysis formula provided by OligoCalc (Kibbe 2007). 
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Det ect ion (Agarose gel elect rophoresis) 
1,5g agarose in 100ml 1xTAE (40mM Tris-acetate, 1mM EDTA in aqua 
bidest) were heated for 80 seconds in the microwave oven. After adding 
10µl of Gel Red, the fluid was poured into the assembled electrophoresis 
chamber (15- or 20-slot comb). After the gel had polymerized, 750ml 1xTAE 
were added. Subsequently, 25µl of the DNA-Marker and the complete 
PCR products were applied and separated using 70V/210mA. The run was 
stopped after the yellow dye ran out of the gel and PCR products were 
photographed using a Herolab gel documentation system. 
 
Identification of signal peptides and transmembrane domains 
 
 
Figure 6 | Overview of working steps for identification of transmembrane 
domains and signal peptides, exon identification and primer choice  by the 
example of FGFR-1 transcript variant 2 (accession number NM_015850). Details 
are described in the text. 
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Figure 6 gives a short overview of the workflow for identification of the 
transmembrane domain, exon identification and result ing primer choice. 
Every single step is described below in more detail. The whole procedure 
was done for all exist ing transcript variants of FGF receptors 1-4 (data not 
shown). 
Hydrophobic clust er predict ion 
MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEE
VEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETDNTKPNPVAPYWTSPEKMEKKLHAVPAAKTV
KFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLP
ANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIG
LSHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMN
SGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKD
LSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARG
MEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLG
GSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSFPDT
RSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR 
Table 7 | Protein sequence of FGFR-1 transcript variant 2 (accession number 
NM_015850) 
 
DAS-TMfilter (dense alignment surface) is able to identify hydrophobic 
clusters at high currency and with lower false posit ive rates than classic 
programs because it  compares the results to experimentally documented 
proteins (Cserzo et al 2002, Cserzo et al 2004). Table 7 shows the complete 
protein sequence of FGFR-1 transcript variant 2 (NM_015850p). 
 
 
 
Figure 7 | Summarized output of DAS-TMfilter for FGFR-1 transcript variant 2. 
Hydrophobic clusters reaching a score of 2.5 are tagged as transmembrane 
regions. 
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DAS-TMfilter identified two hydrophobic clusters in this protein sequence. 
The first  one has its maximum at 13 amino acids indicating a signal peptide 
and the second maximum is found at amino acid 384 (figure 7). 
Reverse t ranslat ion of prot eins 
The predicted transmembrane domain of FGFR-1 has the amino acid 
sequence “IIYCTGAFLISCMVG” and was translated back into the 
nucleotide sequence for comparison purposes. Molecular toolkit  is a small 
package of useful programs for t ranslat ion of nucleotide sequences into 
amino acid sequences and vice versa (Bowen 2008). The reverse 
translated nucleotide sequence of the predicted transmembrane domain 
is “ATTATTTATTGTACTGGTGCTTTTCTTATTTCTTGTATGGTTGGT ”. 
 
 
Figure 8 | Cutout of FGFR-1 transcript variant 2 with binding prediction for 
primers FR3, FR5, FR6 and FR8 established with Sequence extractor (Stothard et 
al 2006). Numbers show the nucleotide position, green-colored primers are 
“forward” while red-colored primers are “reverse”. Grey-colored text reflects the 
antisense-strand of the nucleotide sequence. Fragment lengths can be 
determined by clicking the respective primers. 
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Exon ident ificat ion 
“EMBOSS pairwise alignment” (Rice et al 2000) was used for sequence 
alignments of the predicted transmembrane domain with the complete 
nucleotide sequence of FGFR-1 transcript variant 2. Exon 10 was identified 
to contain the transmembrane domain of FGFR-1 (figure 6). 
Primer binding and fragment  lengt h predict ion 
Sequence extractor (Stothard 2006) was used for primer binding and 
fragment length predict ion (figure 8 shows a cutout of FGFR-1 transcript 
variant 2 with primers FR3, FR5, FR6 and FR8). The results were validated 
with UCSC in-silico PCR (Kent et al 2002). 
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5 Results 
 
5.1 Analysis of fibroblast growth factor receptor splice variants 
 
As shown in figures 9-12, fibroblast growth factor receptors exhibit  a great 
variety in expression of splice variants. Although every single variant likely 
has its features, receptors with a transmembrane domain and a signal 
peptide for t ransport to the cell membrane were of major interest in our 
studies. In order to span cell membranes, t ransmembrane domains as well 
as signal peptides contain hydrophobic clusters which can be identified 
by bioinformatic methods as described before. 
 
5.1.1 Fibroblast growth factor receptor 1 
 
Exon 1 corresponds to the signal peptide and is present in all known splice 
variants of FGFR-1. Exons 2-9 represent immunglobuline (Ig)-like ligand 
binding domains with exons 8 and 9 determining I I Ib- and I I Ic-variants and 
therefore specificity in binding FGFs. Exon 10 contains the hydrophobic 
transmembrane domain. Exons 11-19 are situated in the cytoplasm and 
include the split  tyrosine kinase domain and cofactor binding sites as 
described before. Variants ‘b’ of exons 3, 4, 7, 17 and 18 consist  of 
corresponding variant ‘a’ plus a few nucleotides. Primers FR5 (forward) 
and FR7/FR8 (reverse) were chosen for expression analysis result ing in 
detection of all splice variants with a transmembrane domain while 
dist inguishing between splice variant I I Ib and I I Ic. 
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Figure 9 | FGFR-1 splice variants and primer binding. Green-colored primer   
names indicate forward, red-colored primer names reverse primers. Variant I I Ib 
was identified by BLAT (Kent 2002) search with FGFR-1 transcript variant 2 
(NM_015850) as input and does not have an accession number yet. 
 
 
5.1.2 Fibroblast growth factor receptor 2 
The signal peptide is only present in 4 out of 8 splice variants with a 
transmembrane domain. Exons 2-10 represent ligand binding domains, 
where exons 9 and 10 determine splice variants I I Ib and I I Ic. Both forms of 
exon 11, ‘a’ and ‘b’, include the functional t ransmembrane domain. 
‘B’-forms of exons 3 and 21 contain the corresponding ‘a’-form plus a few 
nucleotides. Exons 12-21 encode the split  tyrosine kinase domain and 
cofactor binding sites as described before. Primer pairs FR11 (forward) and 
FR12/FR13 (reverse) enabled detection of all splice variants containing the 
transmembrane domain and a I I Ib/I I Ic-determining exon. 
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Figure 10 | FGFR-2 splice variants and primer binding. Green-colored primer   
names indicate forward, red-colored primer names reverse primers. 
 
 
5.1.3 Fibroblast growth factor receptor 3 
 
There exist  only three different splice variants of FGFR-3. NM_000142 and 
NM_022965 are membrane-bound and represent isoforms I I Ib and I IIc 
(exons 8 and 9). NM_001163213 does not exhibit  a transmembrane domain 
as well as no exon for determining the I I Ib/IIIc splice variant. Therefore, 
primers FR17a (forward) and FR19/FR20 (reverse) were chosen for 
expression analysis. 
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 Figure 11 | FGFR-3 splice variants and primer binding. Green-colored primer   
names indicate forward, red-colored primer names reverse primers. 
 
 
5.1.4 Fibroblast growth factor receptor 4 
 
As described above, no I I Ib/I I Ic splice variant s of FGFR-4 do exist . The ‘b’-
form of exons 1 and 10 contain the complete ‘a’-form plus a few 
nucleotides. As shown in figure 12, splice variant NM_022963 does not  
contain a signal peptide or a transmembrane domain. To exclude this 
isoform, primers FR25 (forward) and FR26 (reverse) were chosen for 
expression analysis. 
 
Figure 12 | FGFR-4 splice variants and primer binding. Green-colored primer   
names indicate forward, red-colored primer names reverse primers. 
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5.2 Expression profile of FGFR isoforms in ovarian cancer cell 
lines 
 
Figure 13 shows the expression pattern of FGFR isoforms in ovarian cancer 
cell lines. The two images represent independent experiments with 
different exposure t imes to account for the lower mRNA expression of 
primary ovarian surface epithelium (OSE) cells.   
 
Figure 13 | RT-PCR expression profile of fibroblast growth factor receptor (FGFR) 
isoforms in human ovarian cancer cell lines. CAOV-3, HEY, HOC-7, SKOV-3, TR-
170, A2774, A-2780, H-134 and OVCAR-3 represent cancer cell lines derived from 
ovarian adenocarcinomas. PA-1 is derived from a teratocarcinoma. IOSE-80, 
IOSE-364 and IOSE-386 cell lines were obtained by immortalization of human 
ovarian surface epithelium. OSE cells were isolated from primary ovarian surface 
epithelium. The two images represent independent experiments with different 
exposure times to account for the lower FGF receptor mRNA expression of 
primary ovarian surface epithelium (OSE) cells. 
 
FGFR-1b is expressed by all cell lines, but cancer cell lines except H-134 
and HOC-7 show much stronger expression than OSE cells. FGFR-1c is 
evenly expressed among cancer and immortalized cell lines and shows a 
stronger expression than in OSE cells. FGFR-4 gives a similar picture of 
expression among cancer cell lines and immortalized cells, which do 
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express considerably more FGFR-4 than OSE cells. When taking a closer 
look to the expression of FGFR-2 and FGFR-3 isoforms, cancer cell lines can 
be divided into 6 groups from expressing none to all FGFR-2 and FGFR-3 
transcript variants (Table 8). 
 
 FGFR-2b FGFR-2c FGFR-3b FGFR-3c 
 
CAOV-3 - - - - 
 
HEY - (+) - - 
 
HOC-7 + - + - 
 
OVCAR-3 + + + - 
 
A-2780 - - + + 
H-134 - - + (+) 
 
PA-1 + + + + 
SKOV-3 + + + + 
TR-170 (+) + + + 
A-2774 + + + (+) 
 
Table 8 | Different expression patterns of FGFR-2 and 
FGFR-3 isoforms in ovarian cancer cell lines. “+” 
normal expression, “(+)” borderline expression, “-“ no 
expression. 
 
Due to the distribut ion in expressing different FGFR isoforms and favorable 
growth propert ies, A-2780, HEY, OVCAR-3 and SKOV-3 were chosen for 
further invest igations (Table 9) 
 
 1b 1c 2b 2c 3b 3c 4 
A-2780 + + - - + + + 
HEY + + - (+) - - + 
OVCAR-3 + + + + + - + 
SKOV-3 + + + + + + + 
        
Table 9 | Expression of FGFR transcript variants in A-
2780, HEY, OVCAR-3 and SKOV-3 cancer cell lines. 
“+” normal expression, “(+)” borderline expression, “-
“ no expression. 
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5.3 Expression profile of FGFs in ovarian cancer cell lines 
 
 
Figure 14 | RT-PCR expression profile of fibroblast growth factors (FGFs) in human 
ovarian cancer cell lines. CAOV-3, HEY, HOC-7, SKOV-3, TR-170, A2774, A-2780, 
H-134 and OVCAR-3 represent cancer cell lines derived from ovarian 
adenocarcinomas. PA-1 is derived from a teratocarcinoma. IOSE-80, IOSE-364 
and IOSE-386 cell lines were obtained by immortalization of human ovarian 
60 
 
surface epithelium. OSE cells were isolated from primary ovarian surface 
epithelium. FGFs are arranged by intrinsic relationship as described in figure 3. 
The two images represent independent experiments with different exposure 
times to account for the lower FGF mRNA expression of primary ovarian surface 
epithelium (OSE) cells. 
 
As previously described, fibroblast growth factors can be arranged in 
subfamilies by homology and binding propert ies. The expression of FGF 
mRNAs was therefore arranged by subfamily identity as mentioned before. 
FGF-1, FGF-2, FGF-5, FGF-20 and FGF-18 are expressed by the majority of 
ovarian cancer cell lines (figure 14). FGF-3, FGF-8, FGF-10, FGF-19, FGF-21 
and FGF-23 are only expressed by some cell lines. A-2780 is expressing the 
greatest number of FGFs by far (figure 14). It  has to be noted that binding 
of FGF-19, FGF-21 and FGF-23 to its receptors is dependent on the 
presence of a co-receptor (α-/β-Klotho). The relevance of these latter 
growth factors regarding survival, proliferat ion and migrat ion of ovarian 
cancer cells can therefore be quest ioned (Sinha et  al 2008, Urakawa et al 
2006). 
 
5.4 Potential autocrine signaling loops in ovarian cancer cells 
 
Fibroblast growth factors and their receptors show a dist inct pattern of 
t issue-specific expression, enabling cell communication while preventing 
undesired autocrine st imulat ion. As was shown for many different t issues, 
cancer cells corrupt this system.  
All ovarian cancer cell lines show de novo expression of FGF-10, a strong 
activator of FGFR-2 I I Ib, which can be found in normal ovarian surface 
epithelial cells. CAOV-3, HEY and H-134 are the only ovarian cancer cells 
that do not express a combination of FGFs/FGFRs with a high mitogenic 
potential. HOC-7, A-2774, TR-170 and OVCAR-3 cells do express the 
combination FGF-10/FGFR-2 I I Ib, but FGF-10 or FGFR-2 I I Ib expression is very 
low. SKOV-3 cells do express low levels of FGF-10 and normal levels of 
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CAOV-3 
 5 + 10 (+) 20 (+) 18 + 
1b + 3,8 39,4 7,3 6,3 
1c + 59 12,5 28,1 4,7 
4 (+) 7 11,5 26,6 52,8 
     
 
Table 10 | Potential autocrine 
signaling loops of different ovarian 
carcinoma cells. All cell lines show 
de novo expression of FGF-10, a 
strong activator of FGFR-2 I I Ib, 
which is expressed in healthy 
ovarian surface epithelial cells. 
Several other potential autocrine 
signaling loops can be identified 
and are examined in detail in the 
text. + normal expression, (+) 
borderline or very low expression, 
green caption: approximately-
equal expression level of ovarian 
surface epithelium (OSE) cells, 
green numbers: combination of 
FGF/FGFR found in OSE cells too; 
blue: overexpression in comparison 
to OSE cells, red: not expressed in 
OSE cells. Numbers are adapted 
from Zhang 2006 and describe 
relative mitogenic activ ities of FGFs 
at the respective FGF receptor 
proportional to the mitogenic 
activ ity of FGF-1 at this FGF 
receptor. White boxes: relative 
mitogenic activ ity <15% . 1b: FGFR-1 
I I Ib, 1c: FGFR-1 I I Ic, 2b: FGFR-2 I I Ib, 
2c: FGFR-2 I I Ic, 3b: FGFR-3 I I Ib, 3c: 
FGFR-3 I I Ic; 4: FGFR-4; 3: FGF-3, 5: 
FGF-5, 8: FGF-8, 9: FGF-9, 10: FGF-10, 
17: FGF-17, 18: FGF-18, 20: FGF-20. 
 
HEY 
 5 + 10 (+) 20 + 18 + 
1b + 3,8 39,4 7,3 6,3 
1c + 59 12,5 28,1 4,7 
2c (+) 25 6,1 68,4 28,9 
4 + 7 11,5 26,6 52,8 
     
 
HOC-7 
 5 + 10 (+) 20 + 18 + 
1b (+) 3,8 39,4 7,3 6,3 
1c + 59 12,5 28,1 4,7 
2b + 5 217 12,3 7,8 
3b + 1 6 44,3 12,5 
4 (+) 7 11,5 26,6 52,8 
     
 
SKOV-3 
 5 + 10 (+) 20 + 8 + 18 + 
1b + 3,8 39,4 7,3 5,3 6,3 
1c + 59 12,5 28,1 57,5 4,7 
2b + 5 217 12,3 5,9 7,8 
2c + 25 6,1 68,4 91,6 28,9 
3b + 1 6 44,3 18,6 12,5 
3c + 11,8 0,8 89,5 209 77,7 
4 + 7 11,5 26,6 102 52,8 
      
 
A-2774 
 5 (+) 3 + 10 (+) 20 + 18 + 
1b + 3,8 34,4 39,4 7,3 6,3 
1c + 59 0,3 12,5 28,1 4,7 
2b + 5 44,6 217 12,3 7,8 
2c + 25 4,2 6,1 68,4 28,9 
3b + 1 1,5 6 44,3 12,5 
3c (+) 11,8 0,6 0,8 89,5 77,7 
4 + 7 5,8 11,5 26,6 52,8 
 
TR-170 
 5 + 10 + 20 + 18 + 
1b + 3,8 39,4 7,3 6,3 
1c + 59 12,5 28,1 4,7 
2b (+) 5 217 12,3 7,8 
2c + 25 6,1 68,4 28,9 
3b + 1 6 44,3 12,5 
3c + 11,8 0,8 89,5 77,7 
4 (+) 7 11,5 26,6 52,8 
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A-2780 
 5 + 3 + 10 + 20 + 8 + 17 + 18 + 
1b + 3,8 34,4 39,4 7,3 5,3 6 6,3 
1c + 59 0,3 12,5 28,1 57,5 22,7 4,7 
3b + 1 1,5 6 44,3 18,6 10,7 12,5 
3c + 11,8 0,6 0,8 89,5 209 111 77,7 
4 + 7 5,8 11,5 26,6 102 85,5 52,8 
        
 
OVCAR-3 
 5 (+) 10 (+) 9 + 20 + 18 + 
1b + 3,8 39,4 7,3 7,3 6,3 
1c + 59 12,5 12,5 28,1 4,7 
2b + 5 217 2,9 12,3 7,8 
2c + 25 6,1 57,2 68,4 28,9 
3b + 1 6 42,7 44,3 12,5 
4 + 7 11,5 10,1 26,6 52,8 
 
PA-1 
 10 
(+) 
8 + 18 + 
1b + 39,4 5,3 6,3 
1c + 12,5 57,5 4,7 
2b + 217 5,9 7,8 
2c + 6,1 91,6 28,9 
3b + 6 18,6 12,5 
3c + 0,8 209 77,7 
4 + 11,5 102 52,8 
    
 
OSE 
 5 + 9 + 20 (+) 18 + 
1b (+) 3,8 7,3 7,3 6,3 
1c + 59 12,5 28,1 4,7 
2b + 5 2,9 12,3 7,8 
2c (+) 25 57,2 68,4 28,9 
3b (+) 1 42,7 44,3 12,5 
4 (+) 7 10,1 26,6 52,8 
 
H-134 
 10 + 18 + 
1b (+) 39,4 6,3 
1c + 12,5 4,7 
3b + 6 12,5 
3c (+) 0,8 77,7 
4 + 11,5 52,8 
 
 
FGFR-2 I I Ib but show high de novo expression of FGFR-3 I I Ic and 
overexpression of FGFR-4 together with their highly activating ligand FGF-8. 
A-2780 is not expressing FGFR-2 I I Ib but shows de novo expression of FGFR-3 
I I Ic together with its highly activat ing ligands FGF-8 and FGF-17 and 
overexpression of FGFR-4 which is activated by FGF-8 too. Numerous other 
combinations of ligands and receptors can be found where one or both 
parts are overexpressed in different ovarian cancer cells. Since their 
mitogenic potential is below or approximately on par with autocrine 
signaling loops found in normal ovarian surface epithelial cells they are not 
considered as high potential candidates for the identification of autocrine 
signaling loops in ovarian cancer cells. 
63 
 
5.5 Modulation of Ras/MAPK and PI3K downstream effectors by 
FGF-1, FGF-2 and conditioned growth medium in ovarian 
cancer cells 
 
One of the first  quest ions when studying a signaling pathway is to verify its 
functionality in the invest igated cell lines. As described previously, FGF-1 is 
the most promiscuous FGFR ligand and capable of activat ing all FGFRs. 
FGF-2 is only binding to I I Ic-variants of FGF receptors 1-3 and to FGFR-4 but 
provides  st rong proliferat ion signals in different  cell lines. As shown in figure 
14, ovarian cancer cells express various FGF ligands suggest ing autocrine 
mechanisms providing survival or proliferat ion signals. Therefore, serum-
depleted cells were either t reated with 5nM FGF-1 or FGF-2 or 1ml of 
condit ioned growth medium (CM) for 5 or 10 minutes. 
 
5.5.1 FGF-1 and FGF-2 trigger activation of the Ras/MAPK pathway, but 
not of the PI3K-pathway in A-2780, OVCAR-3 and SKOV-3 ovarian 
cancer cells 
 
As shown in figure 15, FGF-1 and FGF-2 trigger activat ion of the Ras/MAPK 
(ERK1/2), but not the PI3K (AKT, S6) pathway. Interest ingly, FGF-2 causes a 
much stronger phosphorylat ion of ERK1/2 than FGF-1 in A-2780 and 
OVCAR-3, but not in SKOV-3 cells. Although the situation with condit ioned 
growth medium (CM) is not as clear, ERK1/2 is phosphorylated in all three 
cell lines when treating cells with condit ioned growth medium. 
64 
 
A-2780 
 
OVCAR-3 
 
SKOV-3 
 
Figure 15 | Ligand-dependent phosphorylation of fibroblast growth factor 
receptor (FGFR) downstream effectors in ovarian cancer cells in vitro.  
FGF-1, FGF-2 and conditioned growth medium induce phosphorylation of 
ERK1/2 by different degrees, but do not trigger activation of the PI3-kinase 
pathway (AKT, S6). Serum depleted cells were stimulated with 5nM of FGF-1 or 
FGF-2 or 1ml of conditioned growth medium for 5 or 10 minutes. 
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5.5.2 FGF-1 and FGF-2 are not capable of activating Ras/MAPK in HEY 
ovarian cancer cells 
 
FGF-1 and FGF-2 are not able to trigger activat ion of Ras/MAPK pathway 
and only show minor induction of PI3K pathway in HEY cells in vit ro. Failure 
of Ras/MAPK activat ion is due to the fact that phosphorylat ion levels of 
ERK1/2 are already very high (exposure t ime of pERK in figure 16 is as short 
as feasible). Condit ioned growth medium is able to activate the PI3K 
pathway to a higher degree than FGF-1 or FGF-2 alone, suggest ing that 
HEY cells release growth factors besides FGFs which are capable of 
signaling in an autocrine manner. 
HEY 
 
Figure 16 | Ligand-dependent phosphorylation of fibroblast growth factor 
receptor (FGFR) downstream effectors in HEY ovarian cancer cells. FGF-1, FGF-2 
and conditioned growth medium are not able to induce phosphorylation of 
ERK1/2 because it is already highly activated in HEY cells. Conditioned growth 
medium triggers phosphorylation of PI3K pathway (p-AKT). Serum depleted cells 
were stimulated with 5nM of FGF-1 or FGF-2 or 1ml of conditioned growth 
medium for 5 or 10 minutes. 
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5.6 Influence of FGF-1 and FGF-2 on proliferation of ovarian 
cancer cells in vitro 
 
To work out the effects of FGF ligands on cell growth, a cell proliferat ion 
assay was performed. Cells were seeded and allowed to adhere 
overnight before treating them with different concentrat ions of FGFs (0-
0,1-0,5-1-5-10 nM) for 72 hours. 
 
5.6.1 FGF-2 but not FGF-1 induces cell proliferation in A-2780 and HEY 
ovarian cancer cells 
 
A-2780 
  
HEY 
  
Figure 17 | Effects of FGF-1 and FGF-2 on growth of A-2780 and HEY ovarian 
cancer cells. Crystal v iolet staining. Means ± SD, n=3. Dose-dependent growth 
stimulation after 72 hours  of treatment with FGF-1 or FGF-2. 
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As shown in figure 17, FGF-2 is able to st imulate proliferat ion of A-2780 cells 
by 40% and of HEY cells by 26,5% in proport ion to untreated cells while 
FGF-1 is not capable of doing so. 
 
5.6.2 Neither FGF-1 nor FGF-2 induce cell proliferation in OVCAR-3 and 
SKOV-3 ovarian cancer cells 
 
As shown in figure 18, neither FGF-1 nor FGF-2 is able to induce proliferat ion 
in OVCAR-3 and SKOV-3 ovarian cancer cells in vit ro. This is part icularly 
surprising for OVCAR-3 due to the strong phosphorylat ion of ERK1/2 when 
st imulated with FGF-2 (figure 15). 
OVCAR-3 
  
SKOV-3 
  
Figure 18 | Effects of FGF-1 and FGF-2 on growth of OVCAR-3 and SKOV-3 
ovarian cancer cells. Crystal v iolet staining. Means ± SD, n=3. Dose-dependent 
growth stimulation after 72 hours of treatment with FGF-1 or FGF-2. 
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5.7 Effects of fibroblast growth factors on migration of A-2780, 
HEY and SKOV-3 ovarian cancer cells 
 
Tissue invasion and metastasis are the major sources of mortality in cancer 
patients and this eminently applies to ovarian cancers. To determine the 
influence of fibroblast growth factors on the migrat ion of ovarian cancer 
cells, the scratch-assay protocol of Liang et al 2007 was adapted to 
enable stat ist ical analysis. Unfortunately, it  is necessary to seed the cells at 
very high densit ies and OVACR-3 cells failed to adhere when doing so (it  is 
not possible to let the cells grow until reaching confluence since they 
generate an extracellular matrix-like structure which prevents migrat ion, 
Liang et al 2007). Data can therefore only be shown for A -2780, HEY and 
SKOV-3 cells. Treatment with FGF-2 was only done in A-2780 cells as the 
most promising cell line due to the strong phosphorylat ion of ERK1/2 (figure 
15). 
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Figure 19 | Effects of FGF-1 and FGF-2 on migration of A-2780, HEY and SKOV-3 
ovarian cancer cells. Migration in response to 5nM FGF-1 or FGF-2 versus 
untreated. Calculation of migration distance: mean gt – mean g0 (g… gap 
width, t… time points, n ≥ 5). 
 
A-2780 cells migrate very slowly when compared to HEY and SKOV-3 cells 
and they are not able to close the scratch in a t ime-frame of 48 hours 
(data not shown) and neither FGF-1 nor FGF-2 is able to induce migrat ion 
in those cells. HEY and SKOV-3 cells are much more versat ile and close the 
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scratch after around 6 hours. Treatment with FGF-1 activates migrat ion in 
SKOV-3 and to a higher degree in HEY cells, but the increase is non-
significant in both cases and further experiments are necessary to confirm 
these results. 
 
5.8 Impact of FGFR inhibition on survival and proliferation of 
ovarian cancer cells in vitro 
 
To study the dependence of ovarian cancer cells on FGF signaling, two 
different tyrosine-kinase inhibitors were used. PD173074 is inhibit ing FGFR 1-
3 and FGFR-4 at higher doses, while Dovit inib (CHIR-258) is a more 
promiscuous inhibitor (see table 6 for in vit ro kinase assay data). However, 
the major targets of Dovit inib are FGFR-1, FGFR-3 and VEGFR-2. Cell lines 
were treated with different concentrat ions of inhibitors (0,1 – 0,5 – 1 – 5 – 
10µM) and cell numbers were determined after 72 hours of t reatment. 
 
5.8.1 Fibroblast growth factor receptor signaling is crucial for proliferation 
of A-2780 ovarian cancer cells 
 
Figure 20 | Effects of tyrosine-kinase inhibitors Dovitinib (CHIR-258) and 
PD173074 on growth of A-2780 ovarian cancer cells. Crystal v iolet staining. 
Means ± SD, n=3. Dose-dependent growth inhibition after 72 hours of treatment 
with Dovitinib or PD173074. 
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FGFs are able to induce proliferat ion of A-2780 cells in vit ro (figure 17) and 
trigger strong phosphorylat ion of ERK1/2 (figure 15). As shown in figure 20, 
A-2780 cells are highly sensit ive to inhibit ion of FGFR in vit ro. Corresponding 
IC50-values are 0,83µM for PD173074 and 3,03µM for Dovit inib. 
 
5.8.2 PD173074 but not Dovitinib (CHIR-258) inhibits HEY ovarian cancer 
cell proliferation 
 
Although it  is not possible to st imulate proliferat ion of HEY cancer cells with 
FGFs, FGF receptor signaling might provide ligand-independent benefits 
for cell proliferat ion and survival. As shown in figure 21, HEY cells are 
sensit ive to PD173074 (IC50 = 3,29µM) but resistant to treatment with 
Dovit inib. 
 
Figure 21 | Effects of tyrosine-kinase inhibitors Dovitinib (CHIR-258) and 
PD173074 on growth of HEY ovarian cancer cells. Crystal v iolet staining. Means ± 
SD, n=3. Dose-dependent growth inhibition after 72 hours of treatment with 
Dovitinib or PD173074. 
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5.8.3 Neither PD173074 nor Dovitinib (CHIR-258) inhibits OVCAR-3 ovarian 
cancer cell proliferation at clinical relevant concentrations 
 
As shown in figure 22, OVCAR-3 cells are resistant  to PD173074 treatment 
and show only minor sensit ivity to treatment with Dovit inib (IC50 = 8,44µM). 
 
Figure 22 | Effects of tyrosine-kinase inhibitors Dovitinib (CHIR-258) and 
PD173074 on growth of OVCAR-3 ovarian cancer cells. Crystal v iolet staining. 
Means ± SD, n=3. Dose-dependent growth inhibition after 72 hours of treatment 
with Dovitinib or PD173074. 
 
 
5.8.4 PD173074 and Dovitinib (CHIR-258) exhibit similar dose response 
curves on inhibition of SKOV-3 ovarian cancer cell proliferation 
 
As shown in figure 23, PD173074 and Dovit inib show dose-responsive 
inhibit ion of SKOV-3 cell proliferat ion at doses that can be reached 
clinically. Corresponding IC50-values are 4,62µM for PD173074 and 4,81µM 
for Dovit inib. 
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Figure 23 | Effects of tyrosine-kinase inhibitors Dovitinib (CHIR-258) and 
PD173074 on growth of SKOV-3 ovarian cancer cells. Crystal v iolet staining. 
Means ± SD, n=3. Dose-dependent growth inhibition after 72 hours of 
treatment with Dovitinib or PD173074. 
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6 Discussion 
 
The majority of ovarian cancer cell lines show overexpression of FGFR-1c 
(9/9, 100%), FGFR-1b (7/9, 78%) and FGFR-3b (7/9, 78%) in comparison to 
OSE cells and at least half of them (>5/9, >56%) overexpress FGFR-4 and 
show de novo expression of FGFR-3c. Addit ionally, 44% of the invest igated 
cell lines lost expression of FGFR-2b. When taking a closer look at potential 
signaling loops, some restrict ions have to be considered. Although FGF-1 
and FGF-2 are translocated through the cell membrane, they normally 
stay bound to the cell surface and are only released if the cell is 
damaged. This makes it  unlikely that they trigger autocrine downstream 
signaling (Malecki et al 2004). FGF-5 was originally published as a proto-
oncogene with transforming potential (Zhan et al 1988) but was later 
shown to be induced by serum growth factors like EGF, PDGF and TGF-α 
(Werner et al 1991). The expression must therefore be considered a cell 
culture derived art ifact, but as shown in table 10, FGF-5 is not a strong 
activator of the expressed FGF receptors anyway. The de novo expression 
of FGF-7 in immortalized ovarian surface epithelium cell lines (IOSE-80, 
IOSE-364, IOSE-386) might be a result  of the genomic transformation during 
the immortalizat ion process eliminating their use for comparison when 
evaluating fibroblast growth factor receptor and ligand expression in 
ovarian cancer cells. As mentioned before, the FGF-19 subfamily (FGF-19, 
FGF-21 and FGF-23) is dependent on the expression of Klotho proteins in 
the target cells in order to activate downstream signaling which have not 
been found in other t issues than kidney and liver. De novo expression of 
FGF-10, although very low in most cells, was found in all evaluated cell 
lines and the majority of them expressed its high affinity receptor FGFR-2b, 
leading to an autocrine signaling loop with a strong mitogenic potential. 
Several other potential autocrine loops could be identified too. In fact, 
CAOV-3, HEY and H-134 cells are the only evaluated cell lines without any 
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potential autocrine signaling loop with a strong mitogenic potential 
(compare table 10 and belonging text). 
A-2780 ovarian cancer cells are expressing FGFR-4 and both splice variants 
of FGFR-1 and FGFR-3 (figure 13). They also express a wide variety of FGF 
family members (figure 14). Nevertheless, the MAP kinase signaling system 
is yet not highly active in these cells, but can be induced by FGF-1, to a 
much higher degree by FGF-2 and by condit ioned growth medium (figure 
15). This correlates with the induction of cell growth by FGF-2 (figure 17). 
Correspondingly, cells are highly sensit ive to inhibit ion of FGF receptor and 
to mult i-kinase inhibit ion (figure 20) with IC50-values of 0,83µM for PD173074 
and 3,03µM for Dovit inib. PD173074 is inhibit ing FGF receptors 1-3 with high 
affinity, indicating that FGFR-1, FGFR-3 or both provide crucial signals for 
the proliferat ion of A-2780 cancer cells. Dovit inib is, amongst other targets, 
inhibit ing FGFR-1 and FGFR-3 suggest ing that the growth suppression is due 
to inhibit ion of the same target. As previously mentioned, more 
promiscuous inhibitors like Dovit inib are less potent against FGF receptors 
than specific FGF receptor inhibitors. This could explain the discrepancy in 
growth inhibit ion of Dovit inib and of PD173074. A -2780 cells are expressing 
the broadest range of FGFs of all tested cell lines. Surprisingly, they do not 
exhibit  the former described FGFR-2b / FGF-10 autocrine signaling loop but 
instead show a unique de novo expression of FGF-8 and FGF-17 in 
combination with de novo expression of FGFR-3c and overexpression of 
FGFR-4 result ing in an autocrine signaling loop with a high mitogenic 
potential (table 10). As shown in figure 19, A-2780 cells are not very motile 
compared to HEY and SKOV-3 cells. Neither t reatment with FGF-1 nor 
t reatment with FGF-2 induced migrat ion in these cells. 
HEY ovarian cancer cells express both variants of FGFR-1, small amounts of 
FGFR-2c and moderate levels of FGFR-4 (figure 13) and no autocrine 
signaling loop with a high mitogenic potential was found (table 10). 
Phosphorylat ion of Ras/MAP kinase pathway could not be elevated by 
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t reatment with FGF-1 or FGF-2 due to the high basal levels of ERK1/2 
phosphorylat ion (figure 16, exposure t imes for pERK are as short as 
feasible), suggest ing a const itut ive activat ion within the Ras/MAP kinase 
pathway. Besides, a slight activat ion of the PI3 kinase pathway could be 
observed. As shown in figure 19, HEY cells are very motile and are able to 
close the scratch in the cell monolayer in a t ime-frame of 5 hours. 
Treatment with FGF-1 triggers migrat ion in a non-significant manner while 
FGF-2 induces proliferat ion significantly in these cells (p<0,05, figure 17). 
HEY cells are resistant to treatment with Dovit inib, but exhibit  sensit ivity to 
PD173074. As mentioned before, PD173074 inhibits FGF receptors 1-3 with 
high affinity and FGF receptor 4 at high doses but Dovit inib only affects 
FGF receptors 1-3. The sensit ivity to treatment with PD173074 could 
therefore be due to an activat ing mutation of FGFR-4 similar to the one 
found in MDA-MB-453 breast cancer cells (Roidl et al 2010). 
OVCAR-3 ovarian cancer cells are expressing all FGF receptor splice 
variants except FGFR-3 I I Ic (figure 13). De novo expression of FGF-10 leads 
to an autocrine signaling loop with a very high mitogenic potential (table 
10). The FGF signaling system is highly inducible by FGF-2 and by 
condit ioned growth medium and to a lesser extent by FGF-1 triggering 
phosphorylat ion of ERK1/2. Surprisingly, neither t reatment with FGF-1 nor 
with FGF-2 is able to induce proliferat ion in these cells (figure 18) and they 
are resistant to FGF receptor inhibit ion by PD173074 and exhibit  only minor 
growth suppression when treated with Dovit inib, suggest ing signaling 
mechanisms that are independent from platelet -derived growth factor 
receptor (PDGFR), fibroblast growth factor receptor (FGF) and vascular 
endothelial growth factor receptor (VEGFR). 
SKOV-3 ovarian cancer cells are expressing all seven splice variants of the 
FGF receptor. The simultaneous expression of FGF-8 and FGF-10 leads to 
mult iple potential autocrine signaling loops (FGF-10 / FGFR-2b, FGF-8 / 
FGFR-3c and FGF-8 / FGFR-4). The FGF receptor signaling system in these 
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cells can be slight ly induced by FGF-1, FGF-2 and condit ioned growth 
medium as evidenced by elevated phosphorylat ion of ERK1/2. Neither 
t reatment with FGF-1 nor with FGF-2 was able to induce proliferat ion in 
these cells (figure 18), but a non-significant increase in motility could be 
observed when treating with FGF-1 (figure 19). Treatment with tyrosine 
kinase inhibitors PD173074 and Dovit inib showed equal growth reduction 
curves. Expecting, that PD173074 inhibits FGF receptors at lower doses 
than Dovit inib due to its higher affinity, this indicates that SKOV-3 cells 
receive proliferat ion signals not only from FGFR-1, FGFR-2 and FGFR-3 but 
from other receptors inhibited by Dovit inib as well. 
Fut ure direct ions 
Recombinant, dominant negative FGF receptors are lacking the 
intracellular tyrosine kinase domain, but are capable to dimerize with 
functional receptors preventing transphosphorylat ion and subsequent 
downstream signaling and are available as a research tool for all four FGF 
receptors. The introduction of dominant negative receptors in future 
experiments would be very useful for a more precise characterizat ion of 
the single receptors. However, it  is not possible to knock down a single 
transcript variant with this method and short interference RNA (siRNA) 
could be used to characterize the function of promising transcript variants 
in more detail. 
As mentioned before, mutations in the extracellular domain of FGF 
receptors are quite common and lead to const itut ive activat ion of the 
affected receptor. HEY ovarian cancer cells expose high basal 
phosphorylat ion-levels of ERK1/2 but are sensit ive to inhibit ion by FGF 
receptor inhibitors, indicating that this st rong activat ing signal originates 
from one of the expressed FGF receptors. Sequencing of the FGF 
receptors could therefore be used to evaluate an activat ing mutation in 
these cells. 
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FGF receptors have been identified as targets for cancer therapy and 
inhibit ion of FGFR-dependent signaling was able to overcome resistance 
to standard therapies and showed synergist ic growth inhibit ion effects 
when combined with EGF receptor inhibitors (Fischer et al 2008, Pardo et al 
2002). Ovarian cancer patients usually respond well to the standard 
therapy Cisplat inum, Paclitaxel and their derivat ives, but recurrence 
accompanied by resistances to those chemotherapeutics is quite 
common. Mult i-kinase inhibitors like Dovit inib and BIBF 1120 are current ly in 
evaluation for the treatment of relapsed ovarian cancer patients and the 
combination of standard therapies with different FGF receptor and mult i-
kinase inhibitors should therefore be considered in future studies. 
As was discussed before, de novo expression of fibroblast growth factors in 
combination with FGFR-2b, which is expressed in normal ovarian surface 
epithelium as well as de novo expression of FGF receptors is a common 
event in ovarian cancer cells and condit ioned growth medium was able 
to trigger activat ion of the Ras/MAP kinase pathway by different degrees 
in the evaluated cells. Matrix-associated laser desorpt ion/ionizat ion t ime-
of-flight (MALDI-TOF) mass spectrometry enables analysis of complex 
composites of proteins relat ively cheap and fast and would be a 
convenient method for the evaluation of fibroblast growth factors in 
condit ioned growth medium of ovarian cancer cells. 
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